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OF SWINE DIVERGENT FOR OVULATION RATE 
 
Emily Anne McDonald, M.S. 
University of Nebraska, 2005 
 
Advisor: Brett R. White 
 
The interaction between GnRH and its receptor on gonadotropes within the 
anterior pituitary gland represents a central point for regulation of reproduction. 
Additionally, the close proximity of the porcine GnRHR gene to a quantitative trait locus 
for ovulation rate makes it a positional candidate for genes influencing ovulation rate. We 
isolated the GnRHR gene promoter from three lines of swine (Control, Index and 
Meishan) with different ovulation rates.  Transient transfection of gonadotrope-derived 
αT3-1 cells with vectors containing approximately 5000 bp of GnRHR gene promoter 
fused to the cDNA encoding luciferase resulted in a 2- to 4-fold difference in luciferase 
activity (Index and Meishan, respectively) over the Control promoter.  Reduction of the 
full-length promoter to 1900 bp, mutation of the steroidogenic factor-1 binding element 
within the GnRHR gene promoter for all three breeds, and promoter “swap” experiments 
using the -1900/-1400 bp region of 5’ flanking sequence failed to eliminate the 
differences in promoter activity among lines.  Divergence in promoter activity among 
lines was ablated following reduction of the promoter from 1400 to 1000 bp, indicating 
the presence of a breed-specific element within this region. Sequence analysis of this 
region revealed five single bp substitutions among lines. Electrophoretic mobility shift 
assays (EMSA) using nuclear extracts from αT3-1 cells demonstrated unique binding for 
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the oligonucleotide corresponding to -1245/-1225 bp of the Meishan promoter compared 
to the Control/Index promoter, with competition for binding by NF-κB and Sp1 
consensus oligonucleotides. Furthermore, EMSA using an antibody directed against the 
p65 subunit of NF-κB resulted in a supershift.  However, an Sp1-specific antibody failed 
to supershift the DNA:protein complex.  Transient transfection of αT3-1 cells with 
vectors containing the full-length Meishan promoter harboring mutations spanning this 
region reduced luciferase activity compared to native sequence.  Our results demonstrate 
that increased transcriptional activity of the Meishan GnRHR gene promoter is conferred 
in part via the novel utilization of NF-κB within gonadotropes. 
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CHAPTER I 
 
INTRODUCTION 
 
 Efficiency of swine production is controlled by a number of factors, including the 
number of piglets produced per litter.  Even a slight increase in litter size can have a 
dramatic economic impact for a modern hog production facility (Levis, 2000).  A primary 
determinant of litter size in swine is ovulation rate, the number of oocytes that are 
released following ovulation (Christenson et al., 1993).  Ovulation rate and other 
reproductive traits are centrally regulated by the interaction between gonadotropin-
releasing hormone (GnRH) and its cognate receptor on the surface of gonadotrope cells 
of the anterior pituitary gland.   
 After its pulsatile release from the hypothalamus, GnRH acts at the level of the 
anterior pituitary gland to cause the synthesis and secretion of the gonadotropins; follicle 
stimulating hormone (FSH) and luteinizing hormone (LH).  With their roles in follicle 
recruitment and ovulation (FSH and LH, respectively), the gonadotropins are crucial 
factors to determination of ovulation rate in swine.  In addition, the gonadotropins act at 
the level of the ovary in females to stimulate the production of steroid hormones such as 
progesterone and estrogen.  The steroid hormones, in turn, feedback on both the 
hypothalamus and anterior pituitary gland to regulate subsequent production of GnRH 
and gonadotropins, respectively.   
Within the gonadotrope cell, binding of GnRH to the GnRH receptor (GnRHR) 
on the plasma membrane allows GnRH to elicit a variety of cellular responses.  
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Gonadotropin-releasing hormone receptor, a G-protein-coupled receptor, initiates a 
number of intracellular signaling cascades that culminate in the up-regulation of specific 
genes.  Included are the gonadotropin subunit genes, encoding the unique β-subunits for 
follicle stimulating hormone (FSH) and luteinizing hormone (LH), as well as the 
common glycoprotein hormone α-subunit.  Additionally, the binding of GnRH to its 
receptor results in transcriptional activation of the GnRHR gene, allowing GnRHRs in 
part to be self-regulated.  Thus, the interaction of GnRH with its receptor represents a 
critical point for the regulation of genes involved in reproductive function. 
 In swine, the physiological importance of the GnRHR is accentuated by the 
location of the GnRHR gene on chromosome eight, in close proximity to an identified 
quantitative trait locus (QTL) for ovulation rate in pigs (Figure 1.1; Rohrer et al., 1999).  
Thus, the GnRHR gene is both a physiological and positional candidate for genes 
influencing ovulation rate in swine.  To examine potential differences in transcriptional 
regulation of the GnRHR gene and its implications on determination of ovulation rate, we 
have chosen to utilize three models of swine with divergent ovulation rates; the Control 
white-crossbred, Index and Chinese Meishan lines (Figure 1.1).  Meishan females 
demonstrate significantly greater prolificacy compared to their white-cross or occidental 
breed counterparts (Christenson et al., 1993; White et al., 1993).  On average, Meishan 
females produce four to five more piglets per litter than occidental breeds, largely due to 
ovulation rate (Christenson et al., 1993; White et al., 1993).  Additionally, the Index line 
of swine developed at the University of Nebraska-Lincoln displays an increased 
ovulation rate of approximately 7.4 more oocytes per ovulation and approximately one 
additional piglet per litter when compared to Control females (Johnson et al., 1999).  The  
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Figure 1.1.  Location of the GnRHR gene in close proximity to a QTL for ovulation rate 
on porcine chromosome 8.  To study the relationship between the GnRHR gene and 
ovulation rate, we used lines of swine with divergent ovulation rates; the Control line, 
randomly mated from a white-cross background; the Index line, selected based on an 
index of embryonic survival and ovulation rate; and the Chinese Meishan, exhibiting a 
pronounced increase in prolificacy compared to the Control line. 
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Index line was developed from a white-cross background and selected over 14 
generations based on an index of embryonic survival and ovulation rate (Johnson et al., 
1984).   
These unique models represent a method to examine the relationship between 
transcriptional regulation of the porcine GnRHR gene and the mechanisms underlying 
determination of ovulation rate.  Our laboratory aims to determine if there are differences 
in regulation of GnRHR gene expression within gonadotropes of the anterior pituitary 
gland in females from the Control, Index and Chinese Meishan lines.  The ultimate goal 
of these studies would be to create a transgenic pig line for commercial use that displays 
an increased ovulation rate, and subsequently litter size, without influencing other traits 
such as those associated with growth and carcass composition.  If differential 
mechanisms exist, we will identify the transcription factors and respective binding sites 
that confer breed-specific expression of the porcine GnRHR gene. 
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CHAPTER II 
 
LITERATURE REVIEW 
 
Gonadotropin-Releasing Hormone 
 
Role of GnRH in Reproductive Function of the Female 
Gonadotropin-releasing hormone (GnRH) is a decapeptide essential to 
reproductive function in mammals (Schally et al., 1971).  It is produced in the 
hypothalamus, released into the hypothalamo-hypophyseal portal system, and 
subsequently acts on the gonadotrope cells of the anterior pituitary gland (Conn and 
Crowley, 1994).  Gonadotropin-releasing hormone binds to its seven transmembrane, G-
protein-coupled receptor on the surface of gonadotrope cells of the anterior pituitary 
gland to elicit up-regulation of genes within the cell.   
Binding of GnRH to its receptor results in the synthesis of the α-subunit, common 
to glycoprotein hormones (Conn and Crowley, 1994), as well as the unique β-subunits for 
the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH; 
Figure 2.1).  Mature LH and FSH are heterodimers composed of their respective β-
subunit and the common α-subunit (Conn and Crowley, 1994).  Although suggested by 
many, including Padmanabhan et al. (2003), to be an LH-specific releasing factor, GnRH 
is widely accepted as the hormone directly responsible for the synthesis and secretion of 
both LH and FSH.  In addition, the interaction between GnRH and its cognate receptor on 
the cell surface of gonadotropes stimulates the up-regulation of the GnRH receptor 
(GnRHR) gene itself. 
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Figure 2.1. Diagram of a gonadotrope cell.  GnRH is secreted by neurons in the 
hypothalamus and acts on gonadotrope cells of the anterior pituitary gland.  Binding of 
GnRH to its receptor on the cell surface causes the up-regulation of genes encoding the 
common glycoprotein hormone α-subunit and unique FSHβ- and LHβ-subunit genes, as 
well as the GnRHR itself.  
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Following synthesis and secretion within the anterior pituitary gland, the 
gonadotropins play crucial roles in the female with regard to reproduction.  In the female, 
follicle stimulating hormone is responsible for follicle recruitment and maturation as well 
as oogenesis whereas LH induces ovulation.  Alternatively, FSH is instrumental in 
spermatogenesis in the male, while LH aids in the production of testosterone in the male.  
Secretion of the gonadotropins from the anterior pituitary gland also results in the 
production of steroid hormones in the gonads such as androgens, progesterone and 
estradiol-17β (Conn and Crowley, 1994). The steroid hormones then feedback on both 
the anterior pituitary gland and hypothalamus to regulate the subsequent production of 
GnRH and the gonadotropin hormones.   
 
Pulsatility 
Gonadotropin-releasing hormone is secreted in a pulsatile manner (Conn and 
Crowley, 1994).  It is this pulsatility, as much as the binding of the hormone to its 
receptor, that lends potency to the hormone (Conn and Crowley, 1994).  Chronic 
administration of GnRH agonist initially stimulates gonadotropin secretion, mimicking 
the action of native GnRH; however, gonadotropin secretion is soon inhibited due to the 
loss of pulsatility (Brüssow 1994; Peltoniemi, 1995).  This phenomenon allows GnRH 
agonists to be used as inhibitory agents to GnRH action.  The precise mechanisms by 
which an agonist is able to block GnRH action is not entirely known, although it is 
proposed that the agonist elicits its response by initially causing an immediate loss of 
receptors on the cell surface through receptor internalization.  The agonist then maintains 
the loss of GnRH function by uncoupling the receptor from its internal signal  
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transduction system (Conn et al., 1987). 
The use of an antagonist of GnRH may be slightly more effective in its inhibitory 
actions however, as administration of a GnRH antagonist results in the immediate 
inhibition of gonadotropin secretion (Sanchez et al., 1994).  The importance of pulsatile 
secretion of GnRH allows chronic administration of either an agonist or antagonist to 
serve as an inhibitor of GnRH in the gonadotrope cell.  Although researchers have 
investigated the binding mechanism of agonists more extensively than that of antagonists, 
antagonists appear to bind to the receptor in a manner distinct from that of agonists 
(Samama et al., 1993).  Thus, antagonists may inhibit GnRH effects through a different 
mechanism than that of direct competition for binding sites. 
In studies involving treatment of gilts with Antarelix, a synthetic antagonist of 
GnRH, LH pulse frequency was unaffected when compared to controls, although overall 
LH secretion was suppressed (Brüssow et al., 2001).  Additionally, FSH concentration 
and pulse frequency as well as mean baseline concentrations of either LH or FSH were 
unaffected by Antarelix administration (Brüssow et al., 2001).  Follicular growth and 
number of follicles were similar for gilts treated with the GnRH antagonist compared to 
the control gilts, however treated gilts failed to ovulate (Brüssow et al., 2001), 
presumably because of an inhibition of the LH surge that induces ovulation. 
Additionally, treatment of rats with the GnRH antagonist, Cetrorelix (SB-75), 
results in decreased GnRHR numbers, suggestive of decreased transcription and/or 
translation of the gene as opposed to simple antagonist occupation of receptor binding 
sites on the plasma membrane (Halmos et al., 1996).  These data also illustrate the ability 
of GnRHR to down-regulate its own numbers given prolonged treatment with an 
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antagonist. 
 
Structure 
Gonadotropin-Releasing Hormone.  Mammalian GnRH is composed of ten 
amino acids: pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (Matsuo et al., 1971).  
Although many forms of GnRH exist across vertebrate species, the length of the peptide 
and the amino and carboxyl termini are highly conserved (Millar et al., 2004).  The 
homology between these regions suggests the importance of both termini as well as 
peptide length to functionality of the hormone, including receptor binding and activation 
(Millar et al., 2004).  The mammalian GnRH peptide is highly folded to a specific tertiary 
structure shown to enhance binding affinity for its receptor (Millar et al., 2004).  
Alternatively, non-mammalian GnRH lacks such a conformation and exists in a more 
extended form (Guarnieri and Weinstein, 1996; Maliekal et al., 1997).  The discrepancy 
between tertiary structure of mammalian and non-mammalian forms may explain the 
varied binding affinity seen with various forms of GnRH.   
  
Gonadotropin-Releasing Hormone-II.  In addition to GnRH, many species, 
including primates, ruminants, swine, reptiles, birds, amphibians and fish produce Type II 
GnRH (GnRH-II; Millar, 2003).  The alteration of three amino acids differentiates 
GnRH-II from GnRH (Millar, 2003).  Furthermore, GnRH-II is more highly conserved 
across species than GnRH (Sherwood et al., 1993).  Gonadotropin releasing hormone-II 
has been shown to potentiate a higher FSH to LH ratio compared to GnRH in pituitary 
cells from the chicken (Millar et al., 1986) and male sheep (Millar et al., 2001).  
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Gonadotropin-releasing hormone-II is widely distributed throughout the body, including 
the brain, anterior pituitary gland, immune system and a variety of reproductive tissues 
including the ovary, uterine endometrium and breast (Cheon et al., 2001; Choi et al., 
2001; Chen et al., 2001a; Chen et al., 2002a; 2002b; Pawson et al., 2003).  Additionally, 
work in primates suggested a role for GnRH-II in ovarian function and hormonal 
regulation of pregnancy (Siler-Khodr and Grayson, 2001; Siler-Khodr et al., 2003).  
Although GnRH and GnRH-II are expressed in many of the same tissues, a notable 
exception is the expression of GnRH-II throughout the nervous system (Millar, 2003).  
The precise function of GnRH-II awaits further study; however, it is hypothesized that 
the high degree of conservation of GnRH-II across species may be the result of its ability 
to bind to multiple forms of GnRHR (Millar, 2003). 
 
Gonadotropin-Releasing Hormone Receptor 
 
Isolation of Gene Coding Sequence 
Gonadotropin-releasing hormone receptor is a seven transmembrane, G-protein-
coupled receptor that is expressed primarily in the gonadotrope cells of the anterior 
pituitary gland and was first cloned from an immortalized cell line of murine gonadotrope 
origin, αT3-1 cells (Tsutsumi et al., 1992).  The αT3-1 cell line is used frequently for in 
vitro studies involving GnRHR, due to its endogenous production of GnRHR (Windle et 
al., 1990).  These cells also produce the glycoprotein α-subunit, but lack synthesis of 
either the FSHβ- or LHβ-subunits (Windle et al., 1990).  Since the cloning of the GnRHR 
gene in αT3-1 cells, homologous GnRHR cDNA has been identified in many mammalian 
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species including human (Kakar et al., 1992; Chi et al., 1993), cow (Kakar et al., 1993), 
marmoset (Bryne et al., 1999), pig (Weesner et al., 1994), rat (Eidne et al., 1992; Kaiser 
et al., 1992; Perrin et al., 1993), and sheep (Brooks et al., 1993; Illing et al., 1993).   
Although some differences exist in the GnRHR cDNA sequence among the six 
species identified, the amino acid sequence of the mammalian GnRHR exhibits over 85% 
homology (Cheng and Leung, 2000).  One primary difference in the amino acid 
sequences is the addition of one amino acid in the cow, human, pig and sheep, as 
compared to the mouse and rat (Cheng and Leung, 2000).  Although the GnRHR among 
different mammalian species is highly conserved, there exists very little sequence 
homology between the GnRHR and other G-protein-coupled receptors (Kakar et al., 
2002).  In this way, the GnRHR is unique among G-protein-coupled receptors and 
therefore frequently exhibits differential effects on its target cells. 
 
Tissue Expression 
Pituitary.  Gonadotropin-releasing hormone receptor was originally isolated in 
the anterior pituitary gland, where it was identified as a central regulator of the 
hypothalamic-pituitary-gonadal axis (Tsutsumi et al., 1992).  The functions of GnRH are 
mediated through GnRHR, making the receptor a critical component for maintenance of 
reproductive function.  Although present in a variety of tissues primarily involved in 
reproduction, the role of GnRHR is best characterized in gonadotrope cells of the anterior 
pituitary gland.  Specific mechanisms underlying expression of GnRHRs in the anterior 
pituitary gland are described within this thesis.    
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Placenta.  Gonadotropin-releasing hormone, and consequently GnRHR, exert 
actions on a variety of tissues other than the gonadotrope cells of the anterior pituitary 
gland.  An example of one such tissue is the placenta, where GnRHRs are dynamically 
dispersed throughout gestation (Cheng et al., 2001).  While human placenta possesses 
specific binding sites capable of interacting with either GnRH agonists or antagonists, the 
GnRHR of placental origin appears to exhibit a significantly lower affinity for GnRH 
when compared to the GnRHR of pituitary origin (Currie et al., 1981; Escher et al., 1988; 
Bramley et al., 1992; Cheng and Leung, 2000).  These data may reflect modification of 
GnRH and/or GnRHR for use in tissues other than the anterior pituitary gland.  
Gonadotropin-releasing hormone receptor mRNA has been isolated in both 
cytotrophoblast and syncytiotrophoblast layers of the placenta (Lin et al., 1995), as well 
as in a variety of immortalized cell lines of placental origin (Cheng and Leung, 2000).  
Additionally, studies have shown that GnRH regulates the secretion of human chorionic 
gonadotropin (hCG) from the placenta via a receptor-mediated process (Cheng et al., 
2001).   
 
Ovary.  Gonadotropin-releasing hormone may also play a direct and vital role in 
ovarian function (Cheng et al., 2002), including gene expression, steroidogenesis, oocyte 
maturation, ovulation and follicular atresia (Hsueh and Erickson, 1979; Hillensjo and 
LeMaire, 1980; Leung and Steele, 1992; Billig et al., 1994; Richards, 1994).  Radioligand 
binding assays have also indicated that GnRH binds to cells of the ovary (Reeves et al., 
1980).  Cloning of GnRHR cDNA from the human ovary demonstrate an identical 
sequence to that found in the anterior pituitary of the human (Kang et al., 2000).  Studies 
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have also elucidated the presence of GnRHR on human ovarian surface epithelium 
(Cheng and Leung, 2000), in addition to granulosa (Latouche et al., 1989) and luteal cells 
(Popkin et al., 1983; Bramley et al., 1985).  In fact, treatment with GnRH has been shown  
to inhibit progesterone production in human granulosa cells (Peng et al., 1994). 
 
Cancer Cell Types.  Gonadotropin-releasing hormone presence in a variety of 
tissues demonstrates its importance in biological processes aside from its well-established 
role in regulating the synthesis and secretion of the gonadotropins.  Gonadotropin-
releasing hormone receptor has also been shown to be present in a variety of cancer cell 
types, including pituitary, endometrial, ovarian, breast and prostate cancers (Dondi et al., 
1994; Emons et al., 2000; La Rosa et al., 2000).  Additionally, successful treatments of 
such cancerous cell types include administration of GnRH and its agonists or antagonists 
(Dondi et al., 1994; Emons et al., 2000).  Research also suggests that treatment with a 
GnRH analogue will result in tumor regression via suppression of gonadotropin and 
steroid hormone secretion, of which specific tumor types depend on for survival (Yin et 
al., 1998). 
 
Other Tissue Types.  Gonadotropin-releasing hormone receptor can be found in 
a variety of other tissues including uterine endometrium, prostate, testis, breast, brain and 
blood mononuclear cells (Lefebvre et al., 1980; McCue et al., 1997; Casañ et al., 1998; 
Kakar et al., 2002).  Other reports have revealed the presence of GnRHR in oocytes and 
the developing embryo (Dekel et al., 1988; Casañ et al., 1999; Raga et al., 1999), 
suggesting the importance of GnRHR during early mammalian development.  
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Preliminary results from studies currently underway (Montagner et al., unpublished 
results) suggest the effects of GnRH on early embryonic development occur via an 
autocrine/paracrine mechanism, indicative of embryonic GnRH and GnRHR production. 
 
Structure 
The GnRHR is composed of seven transmembrane domains (Kakar et al., 2002) 
as a member of the G-protein-coupled receptor family (Figure 2.2; Perrin et al., 1989).  
Common to G-protein-coupled receptors, there are cysteine residues present in the first 
and third extracellular loop of GnRHR, indicating the presence of disulfide bonds that are 
known to aid in ligand binding (Kakar et al., 2002; Dohlman et al., 1990).  Despite such 
similarities between the GnRHR and other G-protein-coupled receptors, the GnRHR 
amino acid sequence is divergent from its family members within both the intra- and 
extra-cellular domains (Kakar et al., 2002).  There are also five potential sites for 
phosphorylation within the intracellular loops of the GnRHR (Kakar et al., 2002).  These 
sites may be important in receptor desensitization as well as initiation of specific signal 
transduction cascades (Kakar et al., 2002).  Lack of a C-terminal tail as well as failure to 
bind β-arrestin or undergo ligand-induced phosphorylation also set the mammalian form 
of GnRHR apart from other G-protein-coupled receptors, including other forms of 
GnRHR (McArdle et al., 2002). 
Gonadotropin-releasing hormone receptors appear to be primarily located in low-
density membrane microdomains, as opposed to having a uniform distribution across the 
plasma membrane (Navratil et al., 2003). This localized distribution is the case for most 
G-protein-coupled receptors, following the introduction of a ligand (de Weerd and Leeb-  
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Figure 2.2.  Schematic representation of the GnRH receptor.  The GnRH receptor is 
composed of seven membrane-spanning regions, containing intracellular regions vital to 
initiation of various signal transduction cascades and extracellular domains important in 
receptor binding through glycosylation and disulfide bonds, from Neill (2002). 
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Lundberg, 1997; Feron et al., 1997; Navratil et al., 2003).  Data to suggest a GnRH-
independent localization of GnRHR, has been reported in the gonadotrope-derived αT3-1 
cell line and Chinese hamster ovary (CHO) cells; leading to the conclusion that such 
localization is ubiquitous across cell types that produce GnRHR endogenously (Navratil 
et al., 2003).  Localized distribution patterns of GnRHRs may activate different signaling 
cascades within the cell following ligand binding (Navratil et al., 2003). 
 
Forms of GnRH Receptor 
 Receptors Exhibiting a C-terminal Tail.  Multiple forms of GnRHR have been 
identified, primarily in non-mammalian species (Millar et al., 2004).  Cloning of GnRHR 
from catfish (Tensen et al., 1997), chicken (Troskie et al., 1998), frog (Troskie et al., 
1998) and goldfish (Illing et al., 1999) indicate the presence of a C-terminal tail, as 
opposed to the mammalian form of GnRHR that lacks this structure.  The C-terminal tail 
present in the non-mammalian GnRHR appears to be important in mediating the 
processes of receptor internalization and desensitization, as well as alteration of 
expression patterns (Lin et al., 1998; Pawson et al., 1998).   
 
Type II GnRH Receptor.  Studies have shown the presence of multiple forms of 
GnRHR mRNA and protein present in mammalian pituitary samples (Chi et al., 1993; 
Karande et al., 1995; Kakar et al., 1997), suggesting the possibility of a novel GnRH 
receptor present in mammalian tissue as well (Cheng and Leung, 2000).  However, 
Cheng and Leung (2000) have suggested that differences in GnRH binding sites in 
mammalian pituitary tissue are due to post-translational modifications of GnRHR rather 
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than the presence of an alternative form of GnRHR.  The theory proposed by Cheng and 
Leung (2000) was challenged by Millar and coworkers (2001), who reported another 
form of GnRHR, unique from that already identified and specific for GnRH-II conserved 
from fish to mammals (GnRH-IIR; Sherwood et al., 1993; Sealfon et al., 1997).  Also 
cloned at approximately the same time as the ligand, GnRH-II, the GnRH-IIR has a C-
terminal tail, and activates a strikingly different signal transduction pathway compared to 
the GnRHR (Neill et al., 2001).  The two receptors are diverse enough to allow GnRH 
antagonists to elicit agonistic effects on GnRH-IIR (Millar et al., 2001).  As is the case 
with the GnRHR, the GnRH-IIR recruits the Gq/11α protein to activate extracellular 
signal-regulated kinase (ERK), but differs in that GnRH-IIR activates the p38 mitogen-
activated protein kinase (MAPK) as well (Kakar et al., 2002). 
Binding sites for both GnRH and GnRH-II have been identified in endometrial 
and ovarian cancer cells (Gründker et al., 2002).  The two binding sites exhibited 
differential effects on cancer cells, with GnRHR possessing a high affinity and low 
capacity for its ligand (Emons et al., 1993a; Emons et al., 1993b).  Gründker and 
colleagues (2002) suggested that the binding site shown to exhibit a low affinity and high 
capacity for GnRH agonist may in fact be the GnRH-IIR.  The same group reported that 
the GnRH-IIR present in these cancer cells had greater antiproliferative effects on the 
cells than the GnRHR.  Such antiproliferative effects took place within the cancer cells 
without the involvement of apoptosis, allowing the researchers to suggest that the GnRH-
IIR may influence the cell cycle (Gründker et al., 2002).   
In contrast to the work by Gründker and coworkers (2002), Millar and associates 
(2004) reported that isolation of a fully functional human GnRH-IIR has been 
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unsuccessful.  Functional GnRH-IIR has been identified in a number of other species 
including primates, swine, and many amphibian and reptile species (Millar, 2003).  The 
lack of a functional GnRH-IIR in the human is due to discrepancies in the cDNA 
sequence resulting in a frameshift mutation and a premature stop codon. However, these 
cDNA alterations may be accommodated for post-translationally, allowing GnRH-IIR to 
elicit its effects while possessing only a nonfunctional GnRH-IIR gene.  Another theory 
is that an incomplete copy of the GnRH-IIR is in fact functional in the human.  
Conformation of either explanation would help clarify the importance of GnRH-IIR in 
the human. 
 
Cell Signaling Pathways 
Initiation of Signaling Cascades.  The initial activation of GnRHR involves a 
series of steps common to many G-protein-coupled receptors, including receptor binding 
and a transition step, in the case of agonists only, resulting in the formation of a ternary 
complex (Millar et al., 2004).  Another model for receptor activation (Samama et al., 
1993) involves the spontaneous recruitment of G-proteins to the receptor.  Such a 
complex is thought to have a higher affinity for GnRH agonists and is stabilized upon 
binding of agonists to the complex. 
It is also possible that different forms of GnRHR are capable of initiating various 
signal transduction cascades (Figure 2.3; Millar, 2004) and, consequently, elicit very 
different responses within the target cell.  Gonadotropin-releasing hormone receptor, the 
primary receptor in mammals, is somewhat unique among the G-protein-coupled 
receptors in that it lacks a C-terminal tail and possesses a relatively short third  
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Figure 2.3.  Signal transduction cascades activated by GnRH within gonadotrope cells.  
Primary intracellular signaling cascades initiated by GnRH include the PKA and PKC 
pathways.  The PKC pathway can subsequently activate a variety of MAPK pathways, 
including JNK and ERK. 
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intracellular loop (Cheng and Leung, 2000).  Both of these features play an important role 
in receptor internalization and desensitization of other G-protein-coupled receptors 
(Cheng and Leung, 2000), implying that there must be an alternate mechanism for down-
regulation of inositol triphosphate (IP3), a crucial component of many signal transduction 
cascades utilized by GnRHR.  Creation of a mutant GnRHR possessing the C-terminus 
from the thyroid releasing hormone receptor (TRHR) resulted in a dramatic increase in 
receptor internalization and desensitization rates (Heding et al., 1998), further 
substantiating the concept that GnRHR must utilize a mechanism diverse from typical G-
protein-coupled receptors in order to elicit its intracellular responses.  The use of G-
protein receptor kinases (GRKs) and β-arrestin may provide one such mechanism for 
GnRHR desensitization (Cheng and Leung, 2000).  In addition, studies have shown that 
homologous desensitization of GnRHR occurs through a variety of serine-threonine 
protein kinases, including protein kinase C (PKC) and protein kinase A (PKA; Cheng and 
Leung, 2000). 
 
Protein Kinase C.  Within gonadotrope cells of the anterior pituitary gland, 
GnRH binding to GnRHR stimulates the G-protein, Gq/11α, which then activates the 
membrane-bound protein, phospholipase Cβ (PLCβ; Millar et al., 2004).  Phospholipase 
Cβ in turn causes the hydrolysis of phosphatidyinositol 4,5-bisphosphate to the second 
messengers, inositol triphosphate (IP3) and diacylglycerol (DAG).  Inositol triphosphate 
mobilizes intracellular calcium from its stores in the endoplasmic reticulum, making it 
readily available in the cytoplasm of the cell.  Alternatively, DAG results in an influx of 
calcium from the extracellular environment, as well as activating PKC and subsequent  
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MAPK pathways (Lin and Conn, 1998).   
Mitogen activated protein kinases have been implicated in signaling cascades 
associated with both G-protein-coupled receptors and receptor tyrosine kinases, 
commonly resulting in cellular proliferation and differentiation (Ohmichi et al., 1994; 
Sim et al., 1995).  Interestingly, despite the apparent inability of the mammalian GnRHR 
to desensitize and slow internalization rate, it was suggested that sustained binding and 
the consequent activation of the GnRHR will result in down-regulation of IP3 receptors 
and calcium mobilization as well as gonadotropin production in the anterior pituitary 
gland (McArdle et al., 1996; Willars et al., 2001).  Some evidence would suggest that the 
inability of GnRHR to desensitize results in a rapid desensitization of the IP3 receptor and 
thus, may contribute to the indirect regulatory effects of GnRHR (Willars et al., 2001). 
In addition to having the ability to activate PLC, GnRHR can also activate 
phospholipase A2 (PLA2) and/or phospholipase D (PLD; Chamson-Reig et al., 2003).  
Opposed to the rapid response of PLCβ in activation of second messengers and release of 
calcium into the cytoplasm, PLA2 and PLD are activated after 1-2 minutes following 
binding of GnRH to its receptor.  This allows for the late activation of second messengers 
such as DAG and subsequent PKC isoforms, in addition to those activated by PLCβ 
(Stojikovic et al., 1994).  In this way, GnRHR and its ligand are capable of initiating 
more long-term effects within the target cell. 
A variety of fatty acids (i.e. arachidonic, linoleic, oleic and linolenic) are capable 
of activating various PKC isoforms following GnRHR activation, without the aid of 
second messengers such as DAG or calcium (Chamson-Reig et al., 2003).  Such a 
mechanism provides another means by which GnRHR can elicit its physiological effects 
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within the target cell (Chamson-Reig et al., 2003).  Studies involving the treatment of 
ovarian tumor cells with the GnRH agonist, buserelin, have shown an inhibition of hCG-
induced progesterone secretion (Chamson-Reig et al., 2003).  Inhibition of PKC, in turn, 
blocked the effects of buserelin treatment without affecting the hCG/progesterone 
response of the cells, illustrating that GnRHR does indeed act through the PKC pathway 
(Chamson-Reig et al., 2003). 
Furthermore, Cheng and coworkers (2000) transiently transfected αT3-1 cells 
with 2297 bp of 5’ flanking sequence of the human GnRHR gene and treated with an 
agonist of GnRH.  The GnRH agonist, D-(Ala6)GnRH, decreased GnRHR transcriptional 
activity significantly, and these effects were ablated by co-treatment with the GnRH 
antagonist, antide.  Interestingly, the decrease in GnRHR promoter activity following 
GnRH agonist treatment was reversed when the cells were treated with an inhibitor of 
PKC activation.  In addition, White and coworkers (1999) treated αT3-1 cells transiently 
transfected with approximately 600 bp of the mouse GnRHR promoter fused to 
luciferase, with phorbol-12-myristate-13-acetate (PMA), an activator of PKC, or GnRH.  
Both treatments mimicked each other, significantly increasing luciferase activity (White 
et al., 1999).  Collectively, these data further substantiate the importance of the PKC 
signal transduction cascade in GnRHR promoter activity within gonadotrope cells.  
Further evidence to substantiate this theory was reported by Haisenleder et al. (1997), 
showing that the frequency of calcium pulses can regulate the activity of the GnRHR 
promoter.  Such data demonstrates the importance of calcium signaling to GnRHR gene 
transcription, placing the PKC pathway, a signal cascade intimately associated with 
calcium influx, as a candidate for the primary second messenger system utilized  
 23 
downstream of the interaction between GnRH and its receptor. 
Mitogen-activated protein kinases consist of a group of signaling proteins 
commonly activated by growth factors  (Minden et al., 1994; Cobb and Goldsmith, 1995) 
and includes ERK, Jun N-terminal kinase (JNK) and p38 MAP kinase cascades 
(Ellsworth et al., 2003b).  Lin and Conn (1999) reported that over-expression of Raf-1, a 
MAPK kinase kinase in the ERK cascade, inhibits GnRHR promoter activity in GGH3 
cells.  Additionally, the researchers demonstrated the ability of an inhibitor of the ERK 
pathway to activate GnRHR promoter activity.  Results such as these in GGH3 cells 
suggest a negative role of ERK signaling in GnRHR gene transcription.  Alternatively, 
inhibition of the ERK pathway in αT3-1 cells inhibited activity of the GnRHR gene 
(Norwitz et al., 1999; White et al., 1999), illustrating the use of divergent GnRH 
signaling pathways in alternative cell types. 
Signaling cascades involving MAPK pathways may also be associated with 
localization of GnRHRs on the plasma membrane.  A unique aspect of GnRHR, when 
compared to other G-protein-coupled receptors, is the localization of GnRHRs on the 
plasma membrane of the target cell.  The microdomains that the GnRHRs appear to form 
on the surface of the target cell are intimately associated with the presence of c-raf 
kinase, an enzyme involved in activation of the ERK signaling pathway (Navratil et al., 
2003).  Much like the GnRHR, the c-raf isoform of raf kinase is associated with low 
density membrane microdomains (Navratil et al., 2003), demonstrating the importance of 
the specific c-raf kinase isoform to intracellular signaling stimulated by the interaction 
between GnRH and GnRHR.   
Furthermore, experiments have shown activation of c-raf kinase following GnRH  
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binding to its receptor (Navratil et al., 2003).  A disruption of GnRHRs on the cell 
surface caused a decrease in GnRHR activation via the ERK pathway (Cheng and Leung, 
2000).  Furthermore, decreased ERK activity leads to a reduction in c-fos gene 
expression, a key factor involved in regulation of gene transcription (Navratil et al., 
2003).  Such an effect on intracellular signaling is not due to a reduction in ligand 
binding, but rather a loss of localization of GnRHRs (Navratil et al., 2003).  This is 
thought to be due to a loss of sufficient coupling of the GnRHR to its Gq protein because 
the loss of ERK signaling in cells with disrupted low density receptor microdomain 
formations can be rescued with phorbol ester (PMA) treatment but not by GnRH 
(Navratil et al., 2003). 
Activation of PKC can lead to activation of a number of MAPK pathways 
including ERK and JNK (Levi et al., 1998).  Reiss and coworkers (1997) demonstrated 
that ERK activation following GnRH stimulation was controlled by PKC and calcium in 
αT3-1 cells.  However, activation of ERK was achieved in a Ras-independent manner.  
Thus, the signaling intermediate, Ras, could not be linked to the MAPK pathways known 
to be activated following GnRH treatment.  Additionally, Levi et al. (1998) observed that 
activation of the JNK pathway was mediated by PKC and other downstream signaling 
molecules (c-Src and CDC42) in αT3-1 cells.  This pathway is apparently activated 
independently from the ERK pathway in the same cell line. 
Although activation of PKC is the most prevalent signal transduction pathway 
initiated by GnRH binding to GnRHR, there may exist a ligand-determined phenomenon 
in which different signal transduction cascades are activated depending on the specific 
ligand that is bound to the GnRHR (Millar et al., 2004).  Results regarding investigation 
 25 
of GnRH signaling via its receptor have demonstrated the utilization of numerous signal 
transduction cascades, depending on the cellular environment.  It is widely accepted, 
however, that GnRH signaling acts largely through PKC-dependent, Ca++-dependent, or 
PKA pathways (Lin and Conn, 1999). 
 
Protein Kinase A.  Cheng and Leung (2001) demonstrated that the human 
GnRHR gene promoter is responsive to forskolin, an adenylate cyclase activator, 
providing evidence that GnRH binding to its receptor stimulates the protein kinase A 
(PKA) signal transduction pathway.  Furthermore, GnRHR promoter activity is 
responsive to 8-Br-cAMP, an analogue of the second messenger, cAMP (Cheng and 
Leung, 2001).  Additionally, treatment with the PKA activator, forskolin, decreased 
GnRHR mRNA levels in αT3-1 cells (Alarid and Mellon, 1995).  Transcription of the 
GnRHR gene can also be stimulated by pituitary adenylate cyclase-activating polypeptide 
(PACAP) via increased cAMP (Pincas et al., 2001).  Sadie and coworkers (2003) showed 
that treatment of αT3-1 cells transiently transfected with a plasmid containing 579 bp of 
the mouse GnRHR promoter with PACAP stimulated GnRHR promoter activity, 
reaching a maximal level after eight hours of treatment.  Similar results were determined 
in cells treated with forskolin, although the greatest increase in promoter activity was 
detected sixteen hours following treatment.  These results remain somewhat controversial 
however, as White et al. (1999) reported no stimulation of murine GnRHR promoter 
activity following forskolin treatment.  In fact, treatment of αT3-1 cells with forskolin 
completely blocked GnRH-stimulated GnRHR promoter activity (White et al., 1999). 
In the PKA pathway, GnRHR is coupled to the G-protein, Gs, a protein  
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made up of three subunits (α, β and γ).  Upon binding of GnRH to its receptor, a 
conformational change in the receptor allows for dissociation of the activated α-subunit 
from the β- and γ-subunits.  The α-subunit consequently activates adenylate cyclase, an 
enzyme responsible for the conversion of adenosine triphosphate (ATP) to cAMP.  The 
cascade continues as cAMP activates PKA, responsible for phosphorylation of a variety 
of other proteins within the cell. Ultimately activation of the PKA pathway results in 
various cellular actions, including stimulation of GnRHR gene transcription. 
Stanislaus et al. (1998) showed that GnRHR is capable of utilizing Gq/11, Gs and 
Gi proteins to initiate signal transduction in both GGH3 cells and primary pituitary cells 
in vitro, implicating adenylate cyclase and the PKA pathway in GnRHR promoter 
activity (Lin and Conn, 1998).  Although there is evidence to suggest that GnRH 
signaling can activate the PKA pathway, prolonged stimulation of this pathway results in 
decreased amounts of available catalytic subunit of the PKA molecule (Richardson et al., 
1990).  Such an event represents a negative feedback mechanism designed to regulate 
cellular responses given prolonged hormone treatment (Cheng and Leung, 2001). 
 
Hormonal Regulation 
Regulation by GnRH.  Regulation of GnRHR is a key aspect of normal 
reproductive function, and is achieved largely due to the actions of GnRH itself (Cheng 
and Leung, 2000).  Changes in GnRHR mRNA levels have been demonstrated to be one 
of the mechanisms by which GnRH up-regulates its cognate receptor (Cheng and Leung, 
2000).  Up-regulation of GnRHR mRNA levels in gonadotrope cells occurs within six 
hours of GnRH treatment (Cheon et al., 2000).  In the estrous cycle of the rat and mouse, 
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changes in GnRHR numbers mimic changes seen in GnRHR mRNA levels, suggesting 
that GnRHR protein numbers are controlled through gene regulation (Bauer-Dantoin et 
al., 1993; Turzillo et al., 1994; Cheng and Leung, 2000).  To further substantiate such a 
claim, Cheon and coworkers (2000) were able to eliminate the up-regulation of GnRHR 
mRNA typically seen following treatment with a GnRH agonist by blocking 
transcriptional activity. Such transcriptional regulation has been shown to involve a 
variety of elements within the 5’ flanking region of the GnRHR gene, responsible for 
both basal expression and GnRH-mediated responses (Cheng and Leung, 2000). 
Studies involving transient transfection assays indicated that treatment with a 
GnRH agonist stimulated GnRHR gene promoter activity (Lin and Conn, 1998).  Using 
GGH3 cells, Lin and Conn (1998) were able to demonstrate an increase in GnRHR 
promoter activity following treatment with buserelin, a GnRH agonist.  Such experiments 
also showed that the cellular response following buserelin treatment was mediated at least 
in part through the cAMP signal transduction cascade (Lin and Conn, 1998).  
Additionally, there exists evidence to suggest that a GnRH-mediated increase in GnRHR 
is controlled through Ca++ and PKC (Huckle et al., 1988), although Braden et al. (1991) 
reported that PKC mediates GnRHR synthesis through a mechanism independent of 
GnRH-induced up-regulation.  Such conclusions are contradicted by studies showing that 
treatment of αT3-1 cells with an activator of PKC had no effect on GnRHR mRNA levels 
(Cheng and Leung, 2000).   
Using the gonadotrope-derived αT3-1 cell line, White et al. (1999) demonstrated 
the responsiveness of GnRHR promoter activity to GnRH stimulation.  A significant 
increase in murine GnRHR promoter activity was observed with treatment of increasing 
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amounts of GnRH, an effect reversed by treatment with the specific GnRH antagonist, 
antide (White et al., 1999).  Additionally, Ellsworth and coworkers (2003) found that 
GnRH stimulation of GnRHR promoter activity involved PKC activation of an activating 
protein-1 (AP-1) element via binding of JunD/FosB and JunD/c-Fos heterodimers. 
 
Regulation by Gonadotropic Hormones.   Gonadotropic hormones, such as 
LH and hCG have been shown to influence the prevalence of GnRHR mRNA, especially 
in the ovary.  Studies have reported a decrease in GnRHR mRNA level following 
treatment with hCG (Peng et al., 1994; Li et al., 1996).  Luteinizing hormone treatment of 
rat granulosa cells also results in a time- and dose-dependent decrease in GnRHR mRNA 
levels (Cheng and Leung, 2000).  In 1983, Ranta and associates demonstrated inhibition 
of LH-induced cAMP production, and subsequent steroidogenesis, by GnRH in the 
ovary.  This, taken with evidence that hCG and LH decreased GnRHR mRNA levels in 
the ovary, leads to the possibility of a negative feedback loop between LH and GnRHR 
(Cheng and Leung, 2000).  A related finding has shown that a similar relationship exists 
between LH produced in the anterior pituitary gland and the hypothalamus, suggesting 
the presence of such a feedback loop in the hypothalamus as well (Cheng and Leung, 
2000). 
 
Regulation by Steroid Hormones.  Steroid hormones have been shown to 
exhibit both negative and positive feedback on gonadotrope cells of the anterior pituitary 
gland, influencing GnRHR numbers on the surface of the gonadotrope (Cheng and 
Leung, 2000).  In rat pituitary cells, chronic in vitro administration of estradiol-17β 
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resulted in increased GnRHR levels, whereas short-term exposure caused a down-
regulation of GnRHR (Menon et al., 1985; Emons et al., 1988).  Kirkpatrick and 
coworkers (1998) suggested a synergistic role of estradiol-17β and GnRH in in vivo 
regulation of GnRHR numbers in the pituitary of the ewe.  Estradiol-17β may in fact 
stimulate the anterior pituitary gland to exhibit increased sensitivity to GnRH during the 
periovulatory period in ewes (Crowder and Nett, 1984). 
In contrast, treatment with progesterone in both the rat and sheep pituitary 
resulted in decreased GnRHR mRNA levels in vivo and in vitro (Wu et al., 1994; Bauer-
Dantoin et al., 1995).  The human GnRHR gene promoter contains a progesterone 
response element (PRE; Fan et al., 1995), enabling progesterone to elicit its effects on 
GnRHR mRNA levels.  The transcriptional regulation of GnRHR by progesterone can 
occur through different isoforms of the progesterone receptor (PR; Cheng et al., 2001).  
In humans, PR-A was shown by Cheng and coworkers (2001) to reduce GnRHR 
promoter activity in pituitary and placental cells, whereas PR-B activated transcription in 
placental cells, but was inhibitory in pituitary cells.  Due to the absence of an estrogen 
response element (ERE) on the GnRHR promoter, researchers suspect that estrogen must 
regulate GnRHR levels through a mechanism other than regulation of transcription 
(Kakar et al., 2002). 
It has also been suggested that GnRHR gene transcription can be regulated in part 
by glucocorticoids (Maya-Núñez and Conn, 2002).  Glucocorticoids, a family of steroid 
hormones that includes cortisol, are commonly associated with stress response in animals 
and can reduce GnRH synthesis as well as circulating LH levels when present at high 
concentrations (Suh et al., 1988; Berga et al., 1989; Chandran et al., 1994).  Treatment of 
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GGH3 cells transiently transfected with the murine GnRHR gene promoter with a 
glucocorticoid antagonist exhibited a down-regulation of GnRHR transcriptional activity 
(Maya-Núñez and Conn, 2002), illustrating the importance of glucocorticoids and the 
glucocorticoid receptor to GnRHR transcriptional activity.  Furthermore, glucocorticoids, 
via their response elements, have been found to influence transcriptional activity of other 
hormone receptor genes active in the anterior pituitary (Nogami et al., 2002), such as the 
growth hormone releasing hormone (GHRH) receptor gene.  This gene possesses 
glucocorticoid response elements as well as a thyroid hormone response element, all of 
which actively regulate the transcriptional activity of this promoter (Nogami et al., 2002).  
This evidence supports a role for glucocorticoids in affecting expression of the GnRHR 
gene. 
 
GnRHR Regulation by Growth Factors.  In addition to being closely regulated 
by a large variety of hormones produced throughout the body, it has been suggested that 
GnRHR is also regulated by various growth factors, including activins (Conn and 
Crowley, 1994; Fernández-Vázquez et al., 1996).  Activin is a growth factor belonging to 
the transforming growth factor-β (TGFβ) family of growth and differentiation factors 
(Massagué, 1990) and has been shown to have a stimulatory effect on GnRHR synthesis 
in rat pituitary cultures (Braden and Conn, 1992).  Activin A can also increase 
transcriptional activity of the GnRHR gene in αT3-1 cells (Fernández-Vázquez et al., 
1996).   
Additionally, Norwitz and coworkers (2002) identified a role for activin in  
augmenting transcriptional activation of the GnRHR gene by GnRH.  The synergistic  
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actions of activin and GnRH are mediated by the formation of a complex of transcription 
factors including Fos/Jun family members, which together bind to an AP-1 element, and 
SMAD proteins (Norwitz et al., 2002).  In studying the role of GnRH and activin in 
regulation of GnRHR gene transcription, Norwitz and colleagues (2002) suggested that 
GnRH binds to its receptor, which induces phosphorylation of the AP-1 subunits, Fos and 
Jun.  Simultaneously, the binding of activin to its receptor initiates a phosphorylation 
event involving cytoplasmic SMAD proteins, which in turn translocate to the nucleus and 
form a complex with the activated AP-1 factor to regulate transcription of the GnRHR 
gene (Norwitz et al., 2002).  Activin also plays a role in basal GnRHR gene transcription 
in the mouse, through its interactions with the GnRHR activating sequence (GRAS; 
Duval et al., 1999). 
 Inhibin also appears to affect GnRHR numbers.  In rat primary pituitary cultures, 
treatment with inhibin decreased the number of GnRHR by approximately 50% (Wang et 
al., 1988), and inhibited the up-regulation of GnRHR synthesis following GnRH 
treatment (Wang et al., 1989; Braden et al., 1990).  However, such an effect may be 
rodent specific, as work with ovine primary pituitary cultures demonstrated an up-
regulation of GnRHR mRNA and protein following inhibin treatment (Laws et al., 1990; 
Gregg et al., 1991; Wu et al., 1994). 
 
Transcriptional Regulation 
 General Characteristics.  In an effort to examine transcriptional regulation of the 
GnRHR gene, 5’ flanking sequence for the gene has been isolated in a variety of 
mammalian species including human (Fan et al., 1995; Kakar et al., 1997), mouse 
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(Albarracin et al., 1994), pig (Jiang et al., 2001; Cederberg et al., unpublished data), rat 
(Reinhart et al., 1997; Pincas et al., 1998), and sheep (Campion et al., 1996).  Although 
there is some 5’ flanking sequence homology among all species, one primary area of 
divergence among the known GnRHR promoters is the presence and location of the 
TATA and CAAT boxes (Cheng and Leung, 2000).  Both rodent promoters are lacking a 
TATA box as well as a CAAT box near the transcriptional start site (Albarracin et al., 
1994; Reinhart et al., 1997; Pincas et al., 1998).  In contrast, the human promoter 
possesses several TATA and CAAT boxes arranged closely to one another, suggesting 
that there are multiple sites of transcription initiation in the human (Fan et al., 1995; 
Kakar et al., 1997).  Fan and coworkers (1995) not only found multiple transcription 
initiation sites, but also a number of polyadenylation sites in the 3’ region of the human 
GnRHR gene.  This suggests that tissue specificity is regulated by different transcripts of 
this gene (Fan et al., 1995). 
A variety of transcription factors can regulate the transcriptional activity of the 
GnRHR gene (Figure 2.4).  Many of the transcription factors identified as being essential 
in regulation of GnRHR transcription are located proximal to the translation start site.  
There exists a body of evidence, however, suggesting the presence of distal regulatory 
regions that influence GnRHR gene expression (Pincas et al., 1998).  As reviewed by 
Cheng and Leung (2000), there have been a number of regulatory regions isolated from 
the human GnRHR promoter that are thought to play a role in the regulation of the 
GnRHR gene.  These regions include: a cAMP response element (CRE), PRE, thyroid 
response element (TRE), PEA-3 binding site, AP-1 element, pituitary-specific response 
element (Pit-1; Fan et al., 1995) and steroidogenic factor-1 (SF-1) binding site. 
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Figure 2.4.  Schematic representation of 5’ flanking sequence for the human, mouse, rat, 
pig and sheep GnRHR genes. Elements conferring cell-specific expression of the GnRHR 
gene in gonadotrope cells for each species are boxed.   
 
 
 
 
 
 
 
GnRHR
-245 -237
GRAS
-600 -336
Mouse:
GnRHR
-245 -237
GnSE
-983
Rat:
GnRHR
-178 -170
GSE
-9100
Sheep:
GnRHR
-179 -171-5000
Pig:
GSE
AP-1
-330-391 -380
GnSE
-962 -871 -862
NRS
-7-15
GSE
GnRHR
-139 -131
AP-1
-4570 -1000
Human:
-994
GSEAP-2
-4564
AP-1 AP-1
-333-340-561-568
Oct-1
-1018 -1009
GSE
-1000
 34 
Activating Protein-1.  Through transient transfection assays in αT3-1 cells, 
Cheng et al. (2000) demonstrated that down-regulation of the human GnRHR gene is 
mediated by an AP-1 binding site.  In this study, Cheng and coworkers showed that AP-1 
abolished the down-regulation typically seen with GnRH agonist treatment, although 
mutation of the AP-1 site failed to affect basal activity of the GnRHR gene promoter.  
This suggests that the AP-1 complex may bind alternate AP-1 sites in different tissues, 
leading to divergent levels of GnRHR promoter activity among tissue types.  Cheng et al. 
(2000) reported an up-regulation of c-fos and c-jun proteins following treatment of αT3-1 
cells with a GnRH agonist suggesting that, although perhaps not directly involved in 
basal expression of the GnRHR gene in humans, AP-1 serves a vital role with regard to 
GnRH regulated expression of the GnRHR gene.  Maya-Núñez and Conn (2002) further 
demonstrated the importance of the AP-1 element on transcriptional activity of the 
GnRHR gene promoter, conferring glucocorticoid responsiveness. 
In 2001, Cheng and Leung identified two AP-1/CREB binding sites within a 
region of the human GnRHR promoter shown to be highly responsive to cAMP.  
Activating protein-1 and CREB have been shown to have the ability to form heterodimers 
and bind to one another’s respective binding sites (Hai and Curran, 1991; Millhouse et 
al., 1998).  Mutational analysis of these sites demonstrated a reduction in forskolin 
stimulation capabilities; however, these mutations failed to completely abolish cAMP 
responsiveness (Cheng and Leung, 2001).  Thus, there may be other transcription factor 
binding sites within the human GnRHR gene promoter that also play a role in cAMP 
responsiveness.  
In the mouse GnRHR promoter, an AP-1 element has been shown to be crucial,  
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not only to basal expression of the gene, but also GnRH stimulation of the GnRHR 
promoter (White et al., 1999).  Through the use of EMSA, White and coworkers 
determined that the complex binding to the AP-1 element located between –336 and –330 
relative to the translation start site in the murine GnRHR promoter was comprised of 
members of the fos and jun families of transcription factors.  Stimulation of the 
transcription factors forming the AP-1 complex occurred via activation of JNK signal 
transduction pathway (Ellsworth et al., 2003). 
Activating protein-1 has also been implicated in mediating the effect of estradiol-
17β on promoter activity of the human GnRHR gene (Cheng et al., 2003).  Research in 
ovarian and breast cancer cell lines showed that estradiol-17β represses the actions of the 
GnRHR gene promoter via estrogen receptor α (ERα; Cheng et al., 2003).  These 
investigators indicated that estrogen-activated ERα repressed human GnRHR gene 
transcription via an indirect mechanism involving CREB-binding protein (CBP) and 
possibly other transcriptional regulators. 
 
Activating Protein-2.  An activating protein-2 (AP-2) binding site within the 
human GnRHR gene promoter has been associated with the PKC signal transduction 
cascade (Kakar et al., 2002).  Using EMSAs, an increase in AP-2 binding was observed 
following treatment of villous trophoblasts with forskolin, an activator of adenylate 
cyclase.  These data also associates AP-2 with the PKA pathway (Knöfler et al., 2004).  
Activating protein-2 has been implicated in activity of the LH receptor (Nikula et al., 
2001) and hCG β-subunit (Johnson and Jameson, 1999; Knöfler et al., 2004) gene 
promoters.  Mutation of three identified AP-2 elements within the hCGβ gene promoter 
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in reporter assays resulted in an 87% drop in transcriptional activity 48 hours after 
transfection (Knöfler et al., 2004).  The importance of AP-2 binding to its response 
element has also been illustrated in a variety of other genes involved in the reproductive 
system such as genes encoding: anti-Mullerian hormone (Lasala et al., 2004); cholesterol 
side-chain cleavage cytochrome p450, critical to progesterone production (Ben-Zimra et 
al., 2002); and cytochrome p450 17α-hydroxylase lyase, important in androgen synthesis 
(Zhang and Veldhuis, 2004).   
 
GATA Family.  The GATA transcription factor family plays a prevalent role in 
gene transcription pertaining to many aspects of reproduction, including regulation of the 
GnRHR gene (LaVoie, 2003).  The mammalian family of GATA transcription factors 
consists of six different factors. GATA-1, -2, and -3 are commonly associated with 
nervous system development and hematopoietic cell lineages (Cantor and Orkin, 2002; 
Patient and McGhee, 2002), whereas GATA-4, -5, and -6 have been most frequently 
implicated in organ development such as the heart, gastrointestinal tract and 
genitourinary system (Molkentin, 2000; Molkentin et al., 2000; Patient and McGhee, 
2002). 
Members of the GATA family of transcription factors can act synergistically with 
other factors to either activate or repress transcriptional activity (LaVoie, 2003).  Such 
transcription factors include friend of GATA (FOG)-1 and -2 which interact with the N-
terminal domain of the GATA factors to bind simultaneously to DNA (Fox et al., 1998; 
Svensson et al., 1999; Tevosian et al., 1999; Gaines et al., 2000).  Alternatively, 
CBP/p300 can interact with the C-terminal domain of GATA to activate gene 
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transcription (Blobel et al., 1998; Kakita et al., 1999; Wada et al., 2000).  In studies 
investigating human GnRHR promoter activity in granulosa cells, two CCAAT enhancer 
binding protein (C/EBP) motifs and one GATA motif acted synergistically to promote 
GnRHR gene expression (Cheng et al., 2002). 
GATA-4 and/or -6 have been shown in the ovary to play an important role in 
transcriptional regulation of a number of genes regulated by the gonadotropins including 
inhibin, aromatase and steroidogenic acute regulatory (StAR) protein (LaVoie et al., 
2003).  Similarly, GnRHR gene expression in granulosa cells of the ovary appears to 
require activation by a GATA family member, although it is unknown whether GATA-4 
or -6 is responsible (Cheng et al., 2002). 
Regarding gene regulation during embryogenesis, both GATA-2 and -3 are 
expressed in the developing anterior pituitary gland, although studies in the mouse 
demonstrated that GATA-3 is expressed for only a short time prior to birth (Suh et al., 
2002; LaVoie, 2003).  In gonadotrope-derived αT3-1 and LβT2 cell lines, GATA factors 
are known to be important in regulation of both the glycoprotein α-subunit and GnRHR 
genes through an SF-1 dependent mechanism (Fowkes et al., 2002; Pincas et al., 2001).   
Additionally, perhaps due to the immature nature of αT3-1 cells (Windle et al., 
1990), either GATA-2 or -3 can cause an increase in transcriptional activity of the 
glycoprotein α-subunit gene promoter (Steger et al., 1994).  In placental choriocarcinoma 
cells, both the glycoprotein α-subunit and GnRHR gene promoters appear to be regulated 
by GATA-2 and -3 (Steger et al., 1994; Cheng et al., 2001). 
 
GnRH Receptor Activating Sequence.  Duval and coworkers (1997) identified a  
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DNA binding element important in murine GnRHR gene promoter activation.  Identified  
as GRAS, the novel binding element was shown to work synergistically with the 
transcription factors SF-1 and AP-1 (Duval et al., 1997).  Transient transfections revealed 
the importance of GRAS to cell-specific expression of GnRHR promoter activity in αT3-
1 cells (Duval et al., 1997). 
The transcription factors comprising an activation complex binding to the GRAS 
element included Smad4, Smad3 (dependent on Smad4), AP-1, and a member of the 
forkhead family of DNA binding proteins, FoxL2 (Ellsworth et al., 2003).  The 
composite nature of GRAS is not surprising given the presence of multiple transcription 
factor binding sites.  Smad proteins are often incapable of binding DNA effectively on 
their own (Whitman et al., 1998).  Therefore, Smad proteins commonly bind to DNA in 
conjunction with other factors to activate transcription (Whitman et al., 1998; Germain et 
al., 2000).  Analysis of the murine GRAS binding element using 2 bp transversion 
mutations suggested that Smad4 binding may be localized at the 5’ end of the binding 
sequence (Ellsworth et al., 2003), leaving the remaining sequence open to bind AP-1 
and/or FoxL2.  Furthermore, the central region of the GRAS binding sequence was 
shown by Ellsworth and coworkers (2003) to be essential for AP-1 binding, with 
functionality of the GRAS element reduced by inability of any of the transcription 
factors, Smad4, AP-1, and/or FoxL2, to bind the DNA. 
 
LIM-Related Factors.  The LIM family of proteins includes Lhx2, Lhx3, Isl I, 
and Lmx I (Pincas, et al., 2001).  Specific members of the LIM-related family of factors, 
including Lhx3, are critical during gonadotrope differentiation (Sheng et al., 1996), 
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substantiating their possible role in gene regulation within gonadotrope cells.  
Furthermore, Lhx2 is known to play a role in basal and/or GnRH-stimulated regulation of 
the glycoprotein α-subunit gene in αT3-1 cells (Roberson et al., 1994).  In the rat, 
GnRHR gene transcription is mediated in part by two distal regions (-983/-962 and -871/-
862), termed the GnRHR specific enhancer (GnSE; Pincas et al., 2001).  The GnSE 
region is shown to interact with GATA and LIM-related factors (Pincas et al., 2001), 
illustrating the importance of both families of proteins in transcriptional regulation of 
GnRHR. 
 
Nuclear Factor-κB.  The transcription factor, nuclear factor-κB (NF-κB), has 
been studied extensively in the immune system, although it has also been implicated in a 
number of other biological process, including embryonic development of the mammary 
gland, bone, skin, and central nervous system (Hayden and Ghosh, 2004).  As reviewed 
by Hayden and Ghosh (2004), NF-κB typically exists as a heterodimer composed of p65 
(RelA), p50, p52, RelB and/or c-Rel.  Although p52:p65 and p52:RelB heterodimers are 
prevalent, most commonly, the heterodimer is comprised of the p65 and p50 subunits 
which, prior to activation, remain in the cytoplasm, silenced by binding to the protein 
IκB.  Transcriptional activation of NF-κB involves a cascade of events, beginning with 
degradation of IκB and subsequent release of NF-κB.  Nuclear factor-κB is then free to 
translocate to the nucleus of the cell, where a specific phosphorylation event of the p65 
subunit enhances DNA binding efficiency as well as creating an interaction site for 
binding of the coactivator, CBP/p300. 
 Additionally, NF-κB has been shown to interact with a variety of other 
transcription factors including AP-1, Sp1 and C/EBP (Stein et al., 1993; Oeth et al., 
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1997).  In a study by Gründker and coworkers (2000), GnRH induced activation of NF-
κB in ovarian carcinoma cells in vitro and consequently suppressed apoptosis.  In Sertoli 
cell cultures, NF-κB was shown to interact with SF-1 primarily through the p50 subunit 
(Hong et al., 2003).  Additionally, the p65 subunit of NF-κB inhibited SF-1 activation in 
Sertoli cells in vitro (Hong et al., 2003).  Also in Sertoli cells, NF-κB has been implicated 
as playing a role in stage-specific spermatogenesis (Delfino and Walker, 1998).  Its 
presence in a wide variety of cell types as well as an array of physiological roles, suggest 
that NF-κB is a potential candidate for gene regulation in the anterior pituitary gland. 
 
Nur77.  A nuclear receptor transcription factor with a similar binding site to SF-1, 
Nur77, has been shown to be active in the murine GnRHR promoter as an inhibitor to 
PKA responsiveness (Sadie et al., 2003).  Additionally, Nur77 gene expression is 
upregulated by GnRH in the gonadotrope-derived LβT2 cell line (Sadie et al., 2003), 
further implying the importance of Nur77 in regulating gonadotropic gene expression.  
Potential interactions with other transcription factors known to be regulated by PKA, 
such as AP-2, and the role(s) of Nur77 in GnRHR transcriptional regulation remain to be 
investigated.  
 
Octamer Transcription Factor-1.  Studies involving the 5’ flanking region of 
the human GnRHR gene revealed a binding site, initially referred to as a negative 
regulatory element (NRE), and later determined to contain the binding element for the 
Oct-1 transcription factor (Cheng et al., 2002).  The repressive actions of Oct-1 on human 
GnRHR gene transcription have been shown in a variety of immortalized cell lines 
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including human ovarian OVCAR-3 cells, human placental JEG-3 cells, and αT3-1 cells 
(Cheng et al., 2002).  In addition, mutation of a single base in the recognition site for Oct-
1, (AAAC to AAAG) failed to alleviate the repressive effects of the Oct-1 transcription 
factor (Cheng et al., 2002).  This single base mutation changes the human Oct-1 
recognition sequence to that of the rodent, yet maintains the repressive effects seen with 
the native human sequence, suggesting the importance of Oct-1 repression in GnRHR 
gene transcription in the human (Cheng et al., 2002). 
 Interestingly, Oct-1 has also been shown to exhibit positive effects on gene 
transcription, depending on the conformation adopted by the transcription factor, which 
depends largely on the binding and flanking sequences (Walker et al., 1994) as well as 
the orientation that the Oct-1 transcription factor binds to the DNA (Verrijzer et al., 
1991).  For example, Oct-1 has been shown to act as an activator via its interaction with 
the TATA binding protein (TBP), high mobility group protein 2, and the TATA box (Luo 
and Roeder, 1995; Zwilling et al., 1994).  The transcription factor Oct-1 is also thought to 
enhance transcriptional activity by recruiting TFIIB, part of the basal transcriptional 
machinery, to the transcription initiation site (Nakshatri et al., 1995).  Thus the 
importance of Oct-1 in gene regulation is illustrated, whether through a mechanism 
involving repression or activation of promoter activity. 
 
Specificity Protein Family.  The specificity protein (Sp) family is composed of 
four members, Sp1, Sp2, Sp3, and Sp4 (Wooten and Ogretmen, 2005).  Three of the Sp 
family members, Sp1, Sp2 and Sp3 are expressed ubiquitously, with Sp4 expressed 
primarily in the nervous system (Wooten and Ogretmen, 2005).  Of the three members 
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expressed throughout mammalian systems, Sp1 and Sp3 display near identical affinity for 
the GC box binding site (Al-Sarraj et al., 2005).  Both Sp1 and Sp3 have been shown to 
regulate transcriptional activity of a large variety of mammalian gene promoters (Majello 
et al., 1994; Oeth et al., 1997; Ping et al., 2000; Wooten and Ogretmen, 2005).  While 
Sp1 most frequently acts as an activator of transcription, Sp3 is reported to function as an 
activator or repressor, depending on the gene of study (Ping et al., 2000).  Interestingly, 
both Sp1 and Sp3 have been implicated in interactions with NF-κB subunits to mediate 
transcription activity (Majello et al., 1994; Oeth et al., 1997; Ping et al., 2000).  Although 
Sp1 appears to be the most well characterized regarding its associations with NF-κB or 
the NF-κB binding element, Sp3 can also associate with NF-κB subunits (Ping et al, 
2000).  Additionally, Sp1 has been implicated in GnRH responsiveness of the LHβ gene 
promoter (Kaiser et al., 1998), illustrating a role for members of Sp family in 
transcriptional regulation within gonadotrope cells.  
 
Steroidogenic Factor-1.  In the human GnRHR promoter, the SF-1 binding site, 
or gonadotrope specific element (GSE), is required for cell-specific expression of the 
GnRHR gene (Ngan et al., 1999).  Transient transfection of αT3-1, monkey kidney Cos-
7, and human ovarian adenocarcinoma SKOV-3 cells with a plasmid containing 2.3 kb of 
human GnRHR 5’ flanking sequence demonstrated the cell-specificity of the GSE, as 
GnRHR promoter activity was observed only in gonadotrope-derived αT3-1 cells (Ngan 
et al., 1999).  Similar results have also been observed in the porcine, sheep, mouse and rat 
GnRHR promoters (Cederberg et al., unpublished data; Duval et al., 1997b; Duval et al., 
2000; Pincas et al., 2001).  The GSE was initially found to be important in regulation of 
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cell-specific expression of the glycoprotein α- and LHβ-subunit genes (Horn et al., 1992), 
demonstrating the importance of the GSE in gene regulation within the anterior pituitary 
gland.  
Research performed with the murine GnRHR gene promoter suggests the 
importance of SF-1 in regulating responsiveness to cAMP (Sadie et al., 2003).  
Steroidogenic factor-1 was shown to have the capability to bind to multiple elements on 
the GnRHR promoter and elicit divergent effects dependent on the binding site.  In 
addition to its direct effects on transcription, SF-1 can also act as a coactivator of other 
transcription factors (Pincas et al., 2001).  It has been demonstrated to interact with Sp1, 
C/EBPβ, Wilm’s tumor 1 (WT-1), SRY-box containing gene 9 (SOX9) and c-jun (Liu 
and Simpson, 1997; De Santa Barbara et al., 1998; Nachtigal et al., 1998; Reinhart et al., 
1999). 
 
Genes Influencing Litter Size 
 Sheep.  The FecB gene in sheep, commonly referred to as the Booroola gene, has 
been associated with increased ovulation rate (Bindon, 1984).  Mutation in the FecB gene 
is associated with an increased number of small follicles that are ovulated when 
compared to wild-type animals (Campbell et al., 2003).  Campbell and coworkers (2003) 
suggested that animals harboring the FecB gene mutation were more sensitive to 
stimulation by gonadotropic hormones, as ewes with the FecB gene mutation and their 
wild-type counterparts exhibited similar hormonal patterns.  The FecB gene mutation has 
recently been identified as a mutation in the bone morphogenic protein 1B (BMP1B) 
receptor gene, altering the kinase domain of the receptor, which consequently results in 
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alteration of the signaling cascade initiated by the receptor (Souza et al., 2001; Wilson et 
al., 2001).  The receptor for BMP1B is expressed during various stages of 
folliculogenesis in the ovary of the ewe and it is thought to supplement the actions of the 
gonadotropic hormones within the ovary (Souza et al., 2002).  In addition, Monniaux and 
associates (2000) correlated the FecB gene mutation with decreased intrafollicular 
insulin-like growth factor (IGF) binding proteins, suggesting that the resultant increase in 
available IGF played a role in increased ovulation rate exhibited by ewes carrying the 
FecB gene mutation. 
 In addition to the FecB gene, the FecXI gene in sheep has also been implicated in 
high prolificacy of sheep (Davis et al., 1991).  Known as Inverdale sheep, the FecXI 
sheep have a mutation in the bone morphogenic protein 15 (BMP15) gene, an oocyte-
derived growth factor of the transforming growth factor β family (Galloway et al., 2000).  
Interestingly, those animals that are heterozygous for the FecXI gene mutation displayed 
an increased ovulation rate compared to wild-type animals, whereas those that are 
homozygous for the FecXI gene mutation are infertile, illustrating the complex and 
important role BMP15 plays in follicular development (Galloway et al., 2000).   
 
 Swine.  Estrogen and its nuclear receptor have long been known to play a crucial 
role in cyclicity and overall reproductive function of mammalian females.  The estrogen 
receptor (ER) gene may also have a direct effect on litter size in swine (Rothschild et al., 
1996).  Initially identified in the Chinese Meishan breed, a specific allele of the ER gene 
is associated with an increase in total piglets born as well as the number of piglets born 
alive (Rothschild et al., 1996).  Additionally, the favorable allele for increased litter size 
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was identified in swine originating from the Large White breed (Rothschild et al., 1996).  
Data using four white-crossbred commercial swine lines provided further evidence for 
the importance of a specific allele of the ER gene in significantly increasing total piglets 
born/litter as well as the number of piglets born alive (Short et al., 1997).   
 A polymorphism in the prolactin receptor (PRLR) gene has been associated with 
genes influencing ovulation rate and subsequent litter size in swine, although the precise 
mechanism by which the PRLR locus may affect the number of piglets born/litter is 
unknown (van Rens et al., 2003).  A study utilizing an occidental/Meishan crossbred line 
of swine demonstrated a significant influence on reproductive traits such as ovarian 
weight, uterine length and placental weight, and also exhibited a direct effect on 
ovulation rate (van Rens et al., 2003).  Thus, there are multiple candidate genes that may 
influence ovulation rate and/or litter size in swine, including the prolactin receptor and 
estrogen receptor genes. 
 
GnRH Receptor in Swine 
 Physiologically, the GnRHR represents a key point of regulation of reproduction 
in swine.  Additionally, the GnRHR gene may be a positional candidate for genes 
regulating porcine reproduction, especially ovulation rate.  A QTL for ovulation rate on 
the p arm of chromosome eight was reported by Rohrer and coworkers (1999).  Fine 
mapping of the QTL for ovulation rate allowed for the development of microsatellite 
markers for seven genes, including the GnRHR gene (Campbell et al., 2003), which was 
located in close proximity to the QTL for ovulation rate (Rohrer et al., 1999).  
Interestingly, a QTL influencing plasma FSH levels in pubertal males (Rohrer et al., 
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2001) was also identified in the same region of porcine chromosome eight.  Plasma FSH 
levels may represent a key candidate for indirect selection of desirable reproductive traits 
(Ford et al., 2001). Thus, the physical relationship between the GnRHR gene and a QTL 
for FSH levels may influence a variety of reproductive traits as well.  Therefore, the 
GnRHR gene represents both a physiological and positional candidate for genes 
influencing ovulation rate. 
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CHAPTER III 
 
MATERIALS AND METHODS 
 
Lines of Swine 
Control Line.  A control white-crossbred line of swine (Control) was used for 
these experiments that has been randomly mated.  Such a line represents animals that are 
seen broadly in commercial hog production today and, consequently, display 
reproductive traits typical for the sows used in the swine industry.  The original 
identification of approximately 5000 bp of 5’ flanking sequence for the porcine GnRHR 
gene (GenBank Accession #AY166667) and subsequent functional studies utilized the 
promoter from this line (Cederberg et al., unpublished data). 
 
Index Line.  The second line of swine used for these studies was a line selected 
on an index of ovulation rate and embryonic survival (Johnson et al., 1984).  The index 
line (Index) was originally developed as a means to select for increased litter size, since 
direct selection for the trait had proved unsuccessful in previous studies (Gama and 
Johnson, 1993).  After 14 generations of selection for ovulation rate and embryonic 
survival, the Index line displayed 1.4 more pigs per litter, with 7.4 more oocytes per 
ovulation compared to animals from the Control line (Johnson et al., 1999).   
 
Chinese Meishan.  The prolific Chinese Meishan breed of swine (Meishan) has 
pronounced genetic divergence from occidental breeds of swine.  Typically, Meishan 
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females produce approximately four to five more pigs per litter than their counterparts 
from occidental breeds, largely due to an increased ovulation rate (Christenson et al., 
1993; White et al., 1993).  Thus, the Meishan breed is an excellent model for examination 
of genes that influence ovulation rate. 
 
Plasmid Preparation 
For all studies described herein, GnRHR gene promoters from three lines of swine 
displaying divergent ovulation rates were utilized.  Previously, our laboratory isolated 
approximately 5000 bp of 5’ flanking sequence for the porcine GnRHR gene (Cederberg 
et al., unpublished data) using inverse polymerase chain reaction (PCR) procedures 
(Huang 1994; Zeiner and Gehring, 1994). The full-length promoter was then sub-cloned 
into the pGL3 basic vector (Figure 3.1; Promega Corp., Madison, WI) using SacI and 
SmaI restriction endonuclease sites. Thus, the test vector contained the full-length porcine 
GnRHR gene promoter fused to the cDNA encoding luciferase.  Using primers specific 
for the full-length porcine GnRHR gene promoter, we isolated this region from genomic 
DNA of swine lines with increased ovulation rates.  The promoters for these lines were 
then placed into luciferase reporter vectors as described above, using SacI and XhoI 
endonuclease sites for the Index promoter, and SacI and NheI sites for the Meishan 
promoter. 
 
Promoter Deletions.  Vectors containing progressively less 5’ flanking sequence 
in the context of the full-length promoter (5000pGL3) for all three lines were constructed 
through the use of restriction endonuclease digestion, followed by removal of 5’ or 3’ 
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Figure 3.1.  The full-length porcine GnRHR gene promoter was sub-cloned into the 
pGL3-basic vector (Promega Corp.).  Inserted into pGL3-basic through the use of SacI 
and SmaI restriction endonuclease recognition sequences, the porcine GnRHR gene 
promoter was able to drive expression of the luciferase gene within the pGL3-basic 
vector. 
 
 
 
 
 
 
Porcine GnRHR 
Gene Promoter 
~5100  bp 
Sac I  11 
Sma I  28 
0
I 1 
28 
 50 
overhangs resulting from restriction digestion.  Appropriate plasmid fragments were 
subsequently subjected to electrophoresis on a 1% agarose gel and extracted from the gel 
(See gel extraction procedures below). Construction of Meishan and Control vectors used 
in the vector “swap” experiment were created through the use of endonuclease digestion 
of the 500 bp within -1900 and -1400 bp of the promoter, and subsequently ligated into 
pGL3 vectors containing full-length promoter from the other line.  For those studies 
involving deletion of an internal region of promoter, restriction endonuclease digestion 
was used to remove large sections of promoter, coupled with PCR techniques in order to 
regenerate specific sequences of promoter.  Primers were designed to amplify the 
proximal 1000 bp of GnRHR gene promoter for all three lines of swine (Table 3.1; 
Integrated DNA Technologies, Coralville, IA).  Polymerase chain reaction was 
performed using Platinum Pfx DNA polymerase (Invitrogen Life Technologies Corp., 
Carlsbad, CA) and the following cycling conditions: Step 1 - 94°C for one minute, Step 2 
- 94°C for 30 seconds, Step 3 - 55°C for 30 seconds, Step 4 - 72°C for 1.5 minutes, Step 
5 - repeat steps two through four (34 times), and Step 6 - 72°C for 10 minutes.  Generated 
products were then allowed to ligate to the appropriate plasmid fragment by incubating at 
15°C overnight.   
 
Block Replacement Mutations.  Plasmids containing block replacement 
mutations of specific elements within the GnRHR gene promoter were constructed 
through the use of primers designed to replace the binding site of interest with a 
restriction enzyme recognition site of the same length.  Both coding and non-coding 
strands of DNA were replicated using PCR, with one of the primers for each reaction 
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TABLE 3.1. PRIMERS USED TO GENERATE THE PROXIMAL 1000 bp OF 
GnRHR GENE PROMOTER 
 
Forward: 5’- AGG CAC TAA TCC AGT GTC TGC -3’ 
Reverse: 5’- CTT TAT GTT TTT GGC GTC TTC C -3’ 
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covering the site of the desired mutation (Tables 3.2 and 3.3; Integrated DNA 
Technologies).  Cycling conditions for the PCR reaction generating each strand with the 
replaced sequence were as follows: Step 1 - 94°C for two minutes, Step 2 - 94°C for 15 
seconds, Step 3 - 55°C for 30 seconds, Step 4 - 68°C for two minutes, Step 5 - repeat 
steps two through four (35 times), and Step 6 - 68°C for 10 minutes. 
 A second PCR reaction was performed using the generated sequences from the 
previous PCR reaction as the template DNA.  Cycling conditions for this PCR reaction 
were the same as above.  Following each PCR reaction, primers and Platinum Pfx DNA 
polymerase (Invitrogen Life Technologies Corp.) were removed from the reaction using 
the QIAquick PCR Purification Kit (Qiagen, Inc., Valencia, CA).  The resulting vectors 
were mutated to contain a NotI restriction endonuclease site (μSF1pGL3 for all three 
lines), an NsiI site (MμNF-κBpGL3) or a SpeI site (MμSp1pGL3) in place of the element 
of interest.  The Mμ1240pGL3 vector was composed of a double mutation of both the 
NF-κB and Sp1 binding sites. 
To purify the PCR reaction, Buffer PB was added and the entire PCR reaction 
was applied to a column and centrifuged using a Biofuge Pico microcentrifuge (Kendro 
Lab Products, Hanau, Germany) at 16,000 x g for one minute.  The column was washed 
with 750 μl of Buffer PE and centrifuged at 16,000 x g for two minutes.  
Deoxyribonucleic acid was removed from the column by application of 50 μl of Buffer 
EB and centrifuged at 16,000 x g for one minute.  Following purification, PCR products 
and vectors containing the full-length GnRHR gene promoter were digested with 
endonucleases to allow for insertion of the PCR product into the appropriate promoter 
region.  DNA fragments were subsequently gel extracted, quantitated, and allowed to  
 53 
 
 
 
 
 
 
 
 
 
TABLE 3.2. PRIMERS USED TO GENERATE BLOCK REPLACEMENT 
MUTATIONS OF THE SF-1 BINDING ELEMENT IN VECTORS CONTAINING 
5000 bp OF THE GnRHR GENE PROMOTER FOR ALL THREE LINES OF SWINE 
 
PCR Reaction Sequence 
Round One  
μSF1 sense forward: 5’- GTT ATG TGG AAG AGC CGG TG -3’ 
μSF1 sense reverse: 5’- AAG TAC ACA AAA CAA GTT GCG GCC GCT CTT TCA CAT TAA ATA TA –3’ 
μSF1 anti-sense forward: 5’- TAT ATT TAA TGT GAA AGA GCG GCC GCA ACT TGT TTT GTG TAC TT –3’ 
μSF1 anti-sense reverse: 5’- CTT TAT GTT TTT GGC GTC TTC C –3’ 
Round Two  
Forward: 5’- GTT ATG TGG AAG AGC CGG TG -3’ 
Reverse: 5’- CTT TAT GTT TTT GGC GTC TTC C -3’ 
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TABLE 3.3. PRIMERS USED TO GENERATE BLOCK REPLACEMENT 
MUTATIONS IN VECTORS CONTAINING 5000 bp OF THE MEISHAN GnRHR 
GENE PROMOTER 
 
PCR Reaction Sequence 
Round One  
MμSp1 sense forward: 5’- AGG CAC TAA TCC AGT GTC TGC -3’ 
MμSp1 sense reverse: 5’- ACA GTA TCA TCC AGG CCC ATG CAT AGC TTC CTT GGT GCT ATG -3’ 
MμSp1 anti-sense forward: 5’- CAT AGC ACC AAG GAA GCT ATG CAT GGG CCT GGA TGA TAC TGT -3’ 
MμSp1 anti-sense reverse: 5’- CTT TAT GTT TTT GGC GTC TTC C –3’ 
MμNF-κB sense forward: 5’- AGG CAC TAA TCC AGT GTC TGC -3’ 
MμNF-κB sense reverse: 5’- CTG CAC ACA GTA TCA TCC ACT AGT TGA GGA AGC TTC CTT GGT -3’ 
MμNF-κB anti-sense forward: 5’- ACC AAG GAA GCT TCC TCA ACT AGT GGA TGA TAC TGT GTG CAG -3’ 
MμNF-κB anti-sense reverse: 5’- CTT TAT GTT TTT GGC GTC TTC C –3’ 
Mμ1240 sense forward: 5’- AGG CAC TAA TCC AGT GTC TGC -3’ 
Mμ1240 sense reverse: 5’- CTG CAC ACA GTA TCA TCC ACT AGT ATG CAT AGC TTC CTT GGT GCT ATG –3’ 
Mμ1240 anti-sense forward: 5’- CAT AGC ACC AAG GAA GCT ATG CAT ACT AGT GGA TGA TAC TGT GTG CAG –3’ 
Mμ1240 anti-sense reverse: 5’- CTT TAT GTT TTT GGC GTC TTC C –3’ 
Round Two  
Forward: 5’- AGG CAC TAA TCC AGT GTC TGC -3’ 
Reverse: 5’- CTT TAT GTT TTT GGC GTC TTC C -3’ 
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ligate at 15°C overnight. 
 
Gel Extraction.  Appropriate plasmid fragments were extracted from agarose 
gels with the Qiaex II Agarose Gel Extraction Kit (Qiagen, Inc.).  Excised gel slices were 
weighed and buffer QX1 was added, followed by the addition of QIAEX II reagent.  Gel 
slices were incubated at 55°C for 10 minutes and vortexed every two minutes.  Samples 
were centrifuged using a Biofuge Pico (Kendro Lab Products) at 16,000 x g for one 
minute and resulting pellets were washed with 500 μl of buffer QX1, followed by two 
washes (500 μl each) with buffer PE.  The pellet was allowed to air dry before it was 
resuspended in 20 μl of tris-chloride (Tris-Cl; pH 8.5) and incubated at 55°C for five 
minutes.  Samples were then centrifuged at 16,000 x g for one minute and the supernatant 
was collected. Another 20 μl Tris-Cl (pH 8.5) was added to the pellet, with the incubation 
and centrifugation process repeated.  Plasmid fragments were then quantitated using A260 
and A280 values that were determined with a Pharmacia GeneQuant spectrophotometer 
(Pfizer, New York, NY) and allowed to ligate at 15°C overnight. 
 
Transformation.  For replication purposes, plasmids were transformed into Rb-
Cl competent DH5α cells (Invitrogen Life Technologies Corp.).  The plasmid ligation 
reaction (5 μl) was added to 50 μl of DH5α cells, gently mixed, and incubated on ice for 
30 minutes.  Cells were then heated to 42°C for 30 seconds, followed by a two minute 
incubation on ice.  The addition of 200 μl of SOB media (2% tryptone, 0.5% yeast  
extract, 8.55 mM sodium chloride, 250 mM potassium chloride, 2 M magnesium 
chloride) preceded a one hour incubation shaking at 37°C.  Depending on the plasmid, 
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100-200 μl of cells were plated on petri dishes containing LB media (Sigma Chemical 
Co., St. Louis, MO) with the addition of ampicillin and incubated inverted overnight at 
37°C. 
 
DNA Extraction 
Alkaline Lysis Mini Plasmid Preparation.  Plasmid DNA was isolated from Rb-
Cl competent DH5α cells (Invitrogen Life Technologies Corp.) for plasmid screening 
purposes.  Two ml of LB media (Sigma Chemical Co.) and 2 μl of ampicillin were 
inoculated with a single colony of DH5α cells containing an ampicillin resistant plasmid 
and allowed to grow, shaking overnight at 37°C.  Cells were pelleted via centrifugation at 
16,000 x g for one minute with a Biofuge Pico microcentrifuge (Kendro Lab Products).  
Following removal of the supernatant, cell pellets were resuspended in 100 μl of GTE 
(100 mM glycine, 500 mM ethylenediaminetetraacetic acid [EDTA], 1 M tris) and 
incubated at room temperature for five minutes.  Sodium hydroxide/sodium dodecyl 
sulfate (200 μl; NaOH/SDS solution) was added to each sample.  Next, the sample was 
mixed gently and allowed to incubate on ice for five minutes.  Samples were incubated 
another five minutes following the addition of 150 μl of potassium acetate (5M) and 
vortexed for two seconds.  Following centrifugation at 16,000 x g, the supernatant was 
placed in a clean 1.5-ml microcentrifuge tube, 800 μl of 100% ethanol was added, and 
tubes were incubated for two minutes at room temperature.  Samples were centrifuged at 
16,000 x g for five minutes, the ethanol was removed, and the pellet was washed with 
100 μl of 70% ethanol.  Following another five minutes of centrifugation at 16,000 x g, 
the pellet was allowed to dry at room temperature and resuspended in 1X tris-
 57 
ethylenediaminetetraacetic acid (TE, pH 8.0).  RNase A (0.5 μl) was added and each 
sample was incubated at 37°C or 30 minutes.  All newly constructed plasmids were 
screened via endonuclease restriction digestion prior to use. 
 
Plasmid Purification.  Following alkaline lysis mini preparation and appropriate 
screening with restriction enzymes, 100 ml of LB (with 150 μl ampicillin) was inoculated 
with remaining broth culture from the alkaline lysis preparation and grown, shaking 
overnight at 37°C.  Cells were isolated from the resulting broth culture by 4°C 
centrifugation at 6,000 x g for 15 minutes using a Sorvall RC2-B centrifuge (Du Pont 
Co., Newton, CT).  Preparation of plasmids for transfection was performed through using 
the Plasmid Purification Midi Kit (Qiagen Inc.).  Cell pellets were resuspended in 4 ml of 
buffer P1 and incubated for five minutes at room temperature, after the addition of 4 ml 
of lysis buffer P2.  Following incubation, 4 ml of precipitation buffer P3 was added to 
each of the samples, and they were incubated on ice for 15 minutes.  Samples were 
subjected to 4°C centrifugation at 20,000 x g for 30 minutes using a Sorvall RC2-B 
centrifuge (Du Pont Co.) prior to being applied to a resin column.   
All columns were equilibrated with buffer QBT before application of the cell 
lysate.  Columns were washed twice with 10 ml of buffer QC and plasmid DNA was 
eluted from the column with the addition of 5 ml of buffer QF.  Plasmid DNA was 
precipitated by adding 3.5 ml of isopropanol, followed by centrifugation at 4°C, spinning 
at 15,000 x g for 30 minutes using a Sorvall RC2-B centrifuge.  Pellets were washed with 
2 ml of 70% ethanol and centrifuged at 4°C for 10 minutes at 15,000 x g in a Sorvall 
RC2-B centrifuge (Du Pont Co.).  After pellets had been allowed to air dry, they were 
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resuspended in 250 μl of Millipore water.  All purified plasmids were quantitated through 
the use of a Lambda EZ 150 spectrophotometer (Perkin Elmer, Boston, MA) and 
screened with restriction endonucleases prior to their use in transient transfection assays. 
 
Cell Culture 
 Cultures of αT3-1 cells (Dr. Pam Mellon, Salk Institute, La Jolla, CA) were 
maintained at 37°C in a 5% CO2 in air environment in αT3-1 media composed of high-
glucose Dulbecco’s modified eagle medium (DMEM) with 2 mM glutamine, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 5% fetal bovine serum and 5% horse serum.  Cultures 
of αT3-1 cells were maintained on 150-mm cell culture plates (Corning Inc., Corning, 
NY) in 20 ml of media. 
 
Transient Transfections  
Day 1.  Transient transfections were performed using a liposome-mediated 
protocol.  On Day 1, αT3-1 cells, typically at 70% confluency, were trypsinized and 
plated for transfection.  The cells were washed with 10 ml of 1X phosphate-buffered 
saline (PBS) twice following aspiration of media.  Cells were trypsinized by adding 3 ml 
of 1X trypsin-EDTA (Mediatech Inc., Herdon, VA), incubating at 37°C in a 5% CO2 in 
air environment for five minutes.  Following incubation, cells were rinsed with 7 ml of 
αT3-1 media, with all cell suspensions collected.  A sample of cells (100 μl) was diluted 
in 900 μl of 1X PBS and 10 μl of this dilution loaded on a hemacytometer for cell counts.   
Approximately two million cells were plated onto 6-well cell culture dishes (Corning 
Inc.) in 2 ml of αT3-1 culture media.   
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Day 2.  The plasmid used as a control for transfection efficiency was composed of 
the Rous Sarcoma Virus promoter fused to the cDNA encoding β-galactosidase (RSV-
βgal, Stratagene, La Jolla, CA).  For each test vector, 291 μl of serum-free DMEM and 9 
μl of Fugene6 reagent (Roche Diagnostics Corp., Indianapolis, IN) were aliquoted into 
1.5-ml microcentrifuge tubes.  As each test vector was transfected in triplicate, sufficient 
quantities to result in 900 ng/well of test vector and 100 ng/well of RSV-βGal control 
vector were added to the microcentrifuge tube. The mixture was then incubated for a 
minimum of 15 minutes prior to adding 96 μl of the mixture (DMEM, Fugene6 and 
vectors) to each well.   
 
Day 3.  Transfected αT3-1 cells were harvested 20-24 hours after transfection.  
Media was aspirated from all wells, followed by two rinses with 1X PBS.  Lysis buffer 
(200 μl; Galacto-Light kit; Applied Biosystems, Bedford, MA) containing 1 M 
dithiothreitol (DTT) was added to each well and the plates were incubated, shaking at 
4°C for 10 minutes.  Cell lysates and buffer were collected and centrifuged at 4°C for two 
minutes at 16,000 x g using a Spectrofuge 16M microcentrifuge (E&K Scientific, 
Campbell, CA).  Lysates (20 μl) were transferred to a white 96-well Microflux2 plate 
(Thermo Labsystems, Franklin, MA).  This was performed in duplicate for respective 
luciferase and β-galactosidase assays.  Plates were analyzed for luciferase and β-
galactosidase activity using the Wallac Victor2 instrument (Perkin Elmer).  Transfections  
were performed a minimum of three times, using three different plasmid preparations. 
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Protein Extraction 
 Cytoplasmic and nuclear protein extracts were obtained from αT3-1 cells for their 
use in electrophoretic mobility shift assays (EMSAs) using the NE-PER® Nuclear and 
Cytoplasmic Extraction Reagents Kit (Pierce Biotechnology, Rockford, IL).  Four plates 
of αT3-1 cells at 70% confluency each were rinsed twice with 10 ml of 1X PBS before 
removing the cells via vigorous washing with buffer containing 10 mM Tris-Cl, 140 mM 
sodium chloride (NaCl), and 1 mM EDTA.  Cells were then removed from the wash 
buffer by centrifugation at 4°C for five minutes using a Beckman TJ-6 centrifuge at 500 x 
g (Beckman, Palo Alto, CA).   
The resultant cell pellet was resuspended in CER I reagent through vortexing for 
15 seconds and incubated on ice for 10 minutes.  Protease inhibitor cocktail (100X stock 
containing 104 mM AEBSF, 80 μM aprotinin, 2 mM leupeptin, 4 mM bestatin, 150 μM 
pepstatin A and 140 μM E-64; Sigma Chemical Co.) and Phosphatase Inhibitor Cocktail 
Set II (100X stock containing 200 mM imidazole, 100 mM sodium fluoride, 115 mM 
sodium molybdate, 100 mM sodium orthovanadate and 400 mM sodium tartrate 
dehydrate; CalBiochem, La Jolla, CA) were added simultaneously with CER I reagent.  
CER II reagent was added to the cells, which were then vortexed and allowed to incubate 
on ice for one minute.  Following incubation, lysed cells were centrifuged at 4°C for five 
minutes using a Spectrafuge 16M microcentrifuge at 16,000 x g (E&K Scientific, 
Campbell, CA), with resulting supernatant transferred to a clean 1.5-ml microcentrifuge 
tube and stored at -80°C.  The remaining pellet was resuspended in NER reagent with the 
addition of protease and phosphatase inhibitor cocktails and incubated on ice for 40 
minutes with vortexing for 15 seconds every 10 minutes.  Finally, lysed nuclei were 
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centrifuged at 4°C for 10 minutes using a Spectrafuge 16M microcentrifuge (E&K 
Scientific) at 16,000 x g before being transferred to a clean 1.5-ml microcentrifuge tube.  
Total protein concentration of nuclear extracts was quantitated using a BCA assay kit and 
the accompanying protocol (Pierce Biotechnology).  Nuclear extracts were stored at         
-80°C in 100 μl aliquots. 
 
Electrophoretic Mobility Shift Assays 
 All oligonucleotides used in EMSAs were annealed prior to use by adding 
complementary oligonucleotides (50 μM each) to 1X NET buffer (1 M NaCl, 10 mM 
EDTA, 100 mM Tris-Cl, pH 7.5) and Millipore water.  Oligonucleotides were first 
denatured by heating to 95°C for 10 minutes and then annealed by incubating at 37°C for 
30 minutes followed by a 30 minute incubation at 25°C.   
 Oligonucleotides were end-labeled with [γ-32P]ATP using polynucleotide kinase 
(PNK; Fermentas Inc., Hanover, MD) and a forward reaction protocol.  Annealed 
oligonucleotide (1 μl) was incubated with 1 μl 10X PNK Buffer A, 4 μl water, 1 μl T4 
PNK and 3 μl [γ-32P]ATP for 30 minutes at 37°C.  Following incubation, 35 μl of water 
was added to all reactions.  Reaction mixtures were then applied to equilibrated 
MicroSpin™ G-25 columns (Amersham Biosciences Corp., Piscataway, NJ) and 
centrifuged at 3,000 x g for two minutes using a Mikroliter microcentrifuge (Hettich AG, 
Bäch, Switzerland).  Following the addition of 10X NET buffer (5 μl) to each reaction, 1 
μl from each reaction mixture was added to 4 ml of scintillation fluid and counted on a  
1900TR liquid scintillation counter (Packard Instrument Co., Meriden, CT).   
 Electrophoretic mobility shift assays were performed by adding 2X Dignam D  
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buffer (20 mM HEPES, 20% glycerol, 0.1 M potassium chloride, 0.2 mM EDTA, 0.5 
mM DTT), 20 mM DTT, and 2 μg poly(dI•dC) (Amersham Biosciences) to 5 μg of   
αT3-1 nuclear extracts.  Probe labeled with [γ-32P]ATP (approximately 100,000 cpm) 
was added, and the reaction was incubated at room temperature for 20 minutes.  In those 
assays that included competitor oligonucleotides, the unlabeled, annealed competitor 
oligonucleotide was added just prior to the addition of radiolabeled probe (Table 3.4).  
For supershift assays, a rabbit polyclonal antibody directed against the p65 subunit of 
NF-κB (Calbiochem) or an equal amount of rabbit IgG (Santa Cruz Biotechnology, Santa 
Cruz, CA) was incubated with nuclear extracts and binding components for 
approximately two hours at 4°C, prior to the addition of probe.  Polyacrylamide gels were 
subjected to electrophoresis in 1X TGE buffer (25 mM tris base, 190 mM glycine, 1 mM 
EDTA) for approximately one hour at 100V prior to the addition of binding reactions, 
with subsequent separation of bound from free probe by electrophoresis at 30 mA for 
approximately 1.5 hours.  Gels were then transferred to blotting paper (3 mm; Whatman, 
Maidstone, England), dried and exposed to Biomax MS film (Eastman Kodak Co., 
Rochester, NY) for 20-24 hours at -80°C before being developed using an SRX-101A 
medical film developer (Konica Corp., Wayne, NJ). 
 
Statistical Analysis   
Data were analyzed using the general linear models (GLM) procedure of the  
Statistical Analysis System (SAS, 2001).  Means for luciferase activity in test vectors 
were compared with control values using Dunnett’s t-test.  Means for luciferase activity 
among test vectors were compared using the least significant differences. 
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TABLE 3.4. CONSENSUS OLIGONUCLEOTIDES USED AS COMPETITORS IN 
ELECTROPHORETIC MOBILITY SHIFT ASSAYS.a    
 
Transcription Factor Binding Sequence 
AP-2 5’- GAT CGA ACT GAC CGC CCG CGG CCC GT -3’ 
NF-κB 5’- AGT TGA GGG GAC TTT CCC AGG C -3’ 
Sp1 5’- AAT CGA TCG GGG CGG GGC GAG C -3’ 
 
aAll consensus oligonucleotides were annealed to the complement strand prior to use. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Porcine 
GnRHR 
Gene 
Promoter 
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CHAPTER IV 
 
Differential Transcriptional Regulation of the GnRH Receptor Gene Promoter 
Between Lines of Swine Divergent for Ovulation Rate is Partially Conferred by 
Nuclear Factor-κB (NF-κB) and Specificity Protein 1 (Sp1)-like Elements. 
 
Abstract 
 The interaction between GnRH and its receptor on gonadotropes within the 
anterior pituitary gland represents a central point for regulation of reproduction. 
Additionally, the close proximity of the porcine GnRH receptor (GnRHR) gene to a 
quantitative trait locus (QTL) for ovulation rate suggests that it is a positional candidate 
for genes influencing ovulation rate. We have isolated 5’ flanking sequence for the 
GnRHR gene from three lines of swine (Control, Index and Meishan) that display 
different ovulation rates.  Transient transfection of gonadotrope-derived αT3-1 cells with 
vectors containing approximately 5000 bp of GnRHR gene promoter fused to the cDNA 
encoding luciferase resulted in a 2- to 4-fold difference in luciferase activity (Index and 
Meishan, respectively) over the promoter from the Control line.  Reduction of the full-
length promoter to 1900 bp, mutation of the steroidogenic factor-1 (SF-1) binding site 
within the GnRHR gene promoter for all three breeds, and promoter “swap” experiments 
using the region located between -1900 and -1400 bp of 5’ flanking sequence failed to 
eliminate the differences in promoter activity among the lines of swine.  A loss of this 
characteristic difference in activity among promoters from each line of swine was 
observed following reduction of the 5’ flanking region from 1400 to 1000 bp, indicating 
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the presence of a breed-specific element(s) within -1400 to -1000 bp of proximal 
promoter. Sequence analysis of this 400 bp region revealed five single bp substitutions 
among lines. Electrophoretic mobility shift assays (EMSA) using nuclear extracts from 
αT3-1 cells revealed differential binding between the oligonucleotide corresponding to 
the -1245 to -1225 bp upstream of the translational start site in the Meishan compared to 
the Control/Index promoter.  Additional EMSAs using competitor consensus oligomers 
for the transcription factors, activating protein-2 (AP-2), nuclear factor-κB (NF-κB) and 
specificity protein 1 (Sp1), revealed effective competition for binding by the NF-κB and 
Sp1 oligonucleotides. Furthermore, EMSA using an antibody directed against the p65 
subunit of NF-κB resulted in a supershift.  However, an Sp1-specific antibody failed to 
supershift the DNA-protein complex. Transient transfection of αT3-1 cells with vectors 
containing the full-length Meishan promoter harboring block replacement mutations 
spanning this region reduced luciferase activity compared to native sequence.  Thus, a 
single bp substitution in the 5’ flanking region of the Meishan GnRHR gene allows for 
novel binding of NF-κB and a protein capable of recognizing the Sp1 consensus binding 
sequence, whereas both Control and Index promoters demonstrated no binding at that 
location. Such divergent binding between promoters from different lines of swine 
indicates a potential mechanism for increased transcriptional activity of the Meishan 
GnRHR gene promoter. Further, our results demonstrate the unique utilization of the NF-
κB signaling system in regulation of gene expression within gonadotropes. 
 
Introduction 
Gonadotropin-releasing hormone, produced in the hypothalamus, travels through  
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the hypothalamo-hypophyseal portal system to bind to its cognate receptor on the surface 
of gonadotrope cells within the anterior pituitary gland.  The interaction between GnRH 
and GnRHR results in the synthesis and secretion of the gonadotropins, follicle 
stimulating hormone (FSH) and luteinizing hormone (LH; Clayton and Catt, 1981; Clarke 
et al., 1983).  The gonadotropins subsequently act on the gonads to cause secretion of 
steroid hormones such as progesterone and estrogen in the female.  In addition, the 
steroid hormones feedback on the anterior pituitary and/or the hypothalamus to regulate 
GnRH and gonadotropin hormone levels. 
Binding of GnRH with its seven transmembrane, G-protein-coupled receptor 
results in the activation of a variety of signal transduction cascades, ultimately resulting 
in the up-regulation of the genes that encode the common α- and unique β-subunits of 
FSH and LH (Hamernik and Nett, 1988; Gharib et al., 1990) as well as the GnRHR itself 
(Sealfon and Millar, 1995).  Therefore, the interaction of GnRH and its receptor on the 
surface of gonadotrope cells within the anterior pituitary gland represents a crucial point 
for regulation of reproductive function in mammals.  In addition, the porcine GnRHR 
gene is located on chromosome eight in close proximity to an identified QTL for 
ovulation rate (Rohrer et al., 1999).  Consequently, the GnRHR gene represents both a 
physiological and positional candidate for genes influencing ovulation rate.  In order to 
investigate the relationship between GnRHR and ovulation rate in swine, we utilized 
three different swine models with varying ovulation rates: a Control white-crossbred line; 
an Index line selected for over 14 generations based on an index of ovulation rate and 
embryonic survival (Johnson et al., 1984); and the Chinese Meishan breed, shown to 
demonstrate an increased litter size compared to white-crossbred and occidental breeds,  
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largely due to ovulation rate (Christenson et al., 1993; White et al., 1993). 
  The GnRHR gene promoter has been extensively studied in other species 
including the mouse, rat, human and sheep.  In the mouse, cell-specific expression is 
conferred by the proximal 500 bp of the GnRHR gene promoter (Clay et al., 1995), and is 
composed of binding sites for SF-1 and activating protein-1 (AP-1) as well a GnRH 
receptor activating sequence (GRAS; Duval et al., 1997a; Duval et al., 1997b).  
Additionally, protein kinase C (PKC) activation of AP-1 appears critical for GnRH 
responsiveness of the murine GnRHR gene promoter (White et al., 1999) and is also 
stimulated via the c-Jun N-terminal kinase (JNK) signaling pathway (Ellsworth et al., 
2003a), whereas GRAS is responsible for activin stimulation of the GnRHR gene 
promoter in the mouse (Duval et al., 1999).  Upon further analysis, the same laboratory 
reported that the GRAS element binds a complex of transcription factors including AP-1, 
Smad3 and 4 and FoxL2, a member of the forkhead family of transcription factors 
(Ellsworth et al., 2003b).  Additionally, Norwitz and coworkers (1999) identified an 
enhancer element, sequence underlying responsiveness to GnRH-1 (SURG-1), important 
to maximal stimulation of GnRHR gene transcription by GnRH.  The importance of PKA 
signaling was also illustrated by the role of a cAMP responsive element (CRE) in 
activation of GnRHR gene transcription (Maya-Núñez and Conn, 1999).   
In addition, the rat GnRHR gene promoter appears consistent with the murine 
GnRHR gene promoter in that basal expression is regulated in much the same fashion as 
the mouse GnRHR gene promoter (Pincas et al., 2001).  However, the rat promoter also 
contains a distal enhancer element located upstream of the region responsible for basal 
expression (Pincas et al., 1998).  The human GnRHR gene promoter has also been 
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demonstrated to bind SF-1 and AP-1, as well as octamer transcription factor-1 (Oct-1; 
Ngan et al., 1999; Cheng et al., 2000; Cheng et al., 2001; Cheng et al., 2002).  Elements 
conferring cell-specific expression of the ovine GnRHR gene promoter remain to be 
examined in detail; however Duval and coworkers (2000) reported an SF-1 binding site 
that mediates basal expression of the GnRHR gene.   
The porcine GnRHR mRNA was sequenced by Weesner and coworkers (1994), 
followed by isolation of genomic sequence that included 1200 bp of 5’ flanking sequence 
(Jiang et al., 2001).  Our laboratory has isolated additional 5’ flanking sequence, 
constructed reporter constructs containing approximately 5000 bp of proximal promoter 
fused to the cDNA encoding luciferase and determined functionality of this vector in 
gonadotrope-derived αT3-1 cells (Cederberg et al., unpublished data). In addition, we 
have determined that an SF-1 binding site as well as an element located in a 50 bp region 
between -1700 and -1650 bp upstream of the translational start site partially comprise the 
cell-specific promoter for the porcine GnRHR gene (Cederberg et al., unpublished data).  
In order to compare transcriptional regulation of the GnRHR gene between the Control, 
Index and Meishan lines of swine, our laboratory has isolated the full-length GnRHR 
gene promoter (approximately 5000 bp) from all three lines of swine and constructed 
luciferase reporter vectors containing these breed-specific promoters.  Herein, we have 
demonstrated that there exists divergent activity among the full-length GnRHR gene 
promoters from the three lines of swine utilizing transient transfections assays in 
gonadotrope-derived αT3-1 cells.  In addition, we have identified a single bp substitution 
within the –1400 to –1000 bp region of 5’ flanking sequence that allows the p65 subunit 
of NF-κB and an unidentified protein able to recognize an Sp1 consensus binding  
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element to bind preferentially to the Meishan GnRHR gene promoter compared to either  
the Index or Control promoters. 
 
Materials and Methods 
Plasmids.  Using primers specific for the porcine GnRHR gene promoter 
originally isolated from the Control line (Cederberg et al., unpublished data), we 
sequenced promoters from genomic DNA of the Meishan and Index lines.  Full-length 
GnRHR gene promoters (~ 5000 bp) from the three lines of swine were sub-cloned into 
the pGL3 basic reporter vector (Promega Corp., Madison, WI).  Studies involving 
constructs containing progressively less 5’ flanking sequence of the GnRHR gene 
promoter for all three lines of swine were generated by restriction endonuclease digestion 
of vectors containing the full-length GnRHR gene promoter for each line.  The promoter 
“swap” vectors containing full-length GnRHR gene promoter with the region from -1900 
to -1400 bp exchanged between Control and Meishan promoters was constructed from 
vectors containing 5000 bp of native sequence.  Restriction endonuclease digestion of the 
internal 500 bp and subsequent ligation of the corresponding region from the promoter 
for the other line of swine was performed.  The MμNF-κBpGL3 and MμSp1pGL3 
plasmids were composed of 5000 bp of 5’ flanking sequence for the Meishan GnRHR 
gene with individual elements mutated to contain either an NsiI (MμNF-κB) or SpeI site 
(MμSp1).  Overlap extension PCR mutagenesis was performed through two rounds of 
PCR in order to specifically mutate the binding element of interest.  The first round of 
PCR utilized primers replacing the binding site of interest with a restriction site, and the 
second round used product from the first round as template to anneal and replicate the 
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mutated element and flanking sequence (Table 3.2).  The Mμ1240pGL3 plasmid was 
composed of a double mutation of the NF-κB and Sp1 sites discussed above.  The vector 
used as a control for transfection efficiency was composed of the Rous Sarcoma Virus 
promoter fused to the cDNA encoding β-galactosidase (RSV-βgal, Stratagene, La Jolla, 
CA).   
 
Transient Transfections.  Cultures of αT3-1 cells (Dr. Pam Mellon, Salk 
Institute, La Jolla, CA) were maintained at 37°C in a humidified 5% CO2 in air 
environment in media composed of high-glucose Dulbecco’s modified eagle medium 
(DMEM) containing 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 5% 
fetal bovine serum and 5% horse serum.  Transfections were carried out using a 
liposome-mediated protocol, Fugene6 (Roche Diagnostics Corp., Indianapolis, IN).  
Briefly, 2 x 106 cells were plated in 6-well culture dishes, and treated with 100 μl of 
DMEM containing 0.9 μg of test vector and 0.1 μg of RSV-βgal control vector.  
Approximately 20-24 hours post-transfection, cells were washed twice with 1X 
phosphate-buffered saline (PBS) and harvested with 200 μl of lysis buffer (100 mM 
potassium phosphate and 0.2% Triton X-100, pH 7.8) and 1 mM dithiothreitol (DTT).  
Lysates (20 μl) were analyzed according to manufacturer’s instructions for activity of 
both luciferase (Promega Corp.) and β-galactosidase (Topix, Applied Biosystems, 
Bedford, MA) using the Wallac Victor2 microplate reader (Perkin Elmer, Boston, MA).  
Luciferase values were divided by β-galactosidase values to adjust for transfection 
efficiency.   
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Electrophoretic Mobility Shift Assays.  Nuclear protein extracts were obtained 
from approximately 2.8 x 108 αT3-1 cells using the NE-PER® Nuclear and Cytoplasmic 
Extraction Reagents Kit (Pierce Biotechnology, Rockford, IL).  The nuclear extracts were 
treated with 1X protease (100X stock; Product No. P 8340; Sigma Chemical Co., St. 
Louis, MO) and phosphatase (100X stock; Catalog No. 524625; CalBiochem, La Jolla, 
CA) inhibitor cocktail solutions to prevent enzymatic degradation of proteins.  
Oligonucleotides were end-labeled with [γ-32P]ATP using T4 polynucleotide kinase 
(Fermentas Inc., Hanover, MD) and purified using sephadex G-25 spin columns 
(Amersham Biosciences Corp., Piscataway, NJ).  Electrophoretic mobility shift assays 
(EMSAs) were completed through incubation of nuclear extracts (5 μg) in 20 μl reactions 
containing 4 μl of Dignam D buffer (20 mM HEPES, 20% glycerol, 0.1 M potassium 
chloride, 0.2 mM EDTA, 0.5 mM DTT), 1 mM DTT, 2 μg of poly(dI•dC) (Amersham 
Biosciences) and, where indicated, a rabbit polyclonal antibody directed against the    
NF-κB p65 subunit (Calbiochem) or an equal amount of rabbit IgG (Santa Cruz 
Biotechnology, Santa Cruz, CA) at 25°C for 30 minutes.  Following incubation, 
radiolabeled probe (100,000 cpm) and 50-fold molar excess of either homologous or 
heterologous unlabeled competitor was added.  Where indicated, 50-fold molar excess of 
unlabeled consensus binding sequence for AP-2, NF-κB or Sp1 (Integrated DNA 
Technologies, Coralville, IA) was also added.  The final reactions were incubated at 25°C 
for 20 minutes before bound probe was separated from free at 30 mA for 1.5 hours on a 
5% polyacrylamide gel that had been prerun at 100 V for 1 hour in 1X TGE (25 mM tris 
base, 190 mM glycine and 1 mM EDTA).  Gels were transferred to blotting paper, dried, 
and exposed to Biomax MS film (Eastman Kodak Co., Rochester, NY) for 20-24 hours at  
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-80°C before being developed.   
 
Statistical Analysis.  Data were analyzed using the general linear models (GLM) 
procedure of the Statistical Analysis System (SAS, 2001).  Means for luciferase activity 
of test vectors were compared with control values using Dunnett’s t-test.  Means for 
luciferase activity among test vectors were compared using the least significant 
differences of least squares means.  All transfections were performed a minimum of three 
times using different plasmid preparations.  Additionally, each plasmid was transfected in 
triplicate wells within each transfection.  
  
Results 
Reporter vectors containing the full-length Control, Index and Meishan 
GnRHR gene promoters display divergent luciferase activity in gonadotrope-
derived αT3-1 cells.  Transient transfections of plasmids containing the full-length 
GnRHR gene promoter (5000 bp) for either the Control, Index or Meishan lines into 
gonadotrope-derived αT3-1 cells were performed.  Vectors containing the Index and 
Meishan GnRHR gene promoters displayed a 2- to 4-fold increase in luciferase activity 
respectively, over the corresponding plasmid containing the promoter from the Control 
line (Figure 4.1).  The difference in promoter activity among the three lines indicates the 
use of divergent mechanisms for transcriptional regulation of the GnRHR gene. 
 
Divergent GnRHR promoter activity among swine lines is unattributable to 
the SF-1 binding site that is a member of the cell-specific promoter for the porcine 
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Figure 4.1.  Luciferase reporter constructs containing the Index and Meishan GnRHR 
gene promoters display 2- and 4-fold increases in activity compared to those containing 
the Control promoter.  Luciferase (LUC) reporter vectors containing 5000 bp of proximal 
GnRHR gene promoter for all three lines of swine were transiently transfected as 
described in Materials and Methods.  Cells were harvested 24 h after transfection and 
assayed for luciferase and β-galactosidase activity.  Luciferase activity was divided by β-
galactosidase activity to adjust for transfection efficiency.  Values represent the mean ± 
SEM of a minimum of three transfections using different vector preparations.  Bars with 
unique letters are different (P < 0.05). 
 
 
 
 
 
 
 
 74 
GnRHR gene.  Previously, our laboratory has identified an SF-1 binding site located at   
-179/-171 bp upstream of the translational start site as a functional member of the cell-
specific promoter for the porcine GnRHR gene (Cederberg et al., unpublished data).  
Such findings led us to investigate the role of the SF-1 binding site with regard to breed 
divergence for GnRHR gene promoter activity.  Mutation of the SF-1 binding site, or 
gonadotrope specific element (GSE), within the context of the full-length promoter, 
completely ablated GnRHR promoter activity for all three lines of swine (Figure 4.2).  
Thus, while the SF-1 binding site is crucial to expression of the porcine GnRHR gene in 
gonadotropes, it is not involved in breed-dependent activity of the GnRHR gene 
promoter. 
 
Breed-specific element(s) of the porcine GnRHR gene promoter lie within 1900 bp 
of 5’ flanking region.  Previous work in our laboratory has shown that cell-specific 
expression of the porcine GnRHR gene is conferred by elements located within 1900 bp 
of proximal promoter (Cederberg et al., unpublished data).  To determine if this region 
contained elements conferring breed-specific expression, we reduced the promoter for all 
three lines of swine from 5000 to 1900 bp upstream of the translational start site.  
Transient transfections of plasmids containing either 5000 or 1900 bp of GnRHR gene 
promoter for each line of swine into αT3-1 cells resulted in maintenance of significant 
differences in luciferase activity among swine lines following reduction of the full-length 
promoter to 1900 bp of 5’ flanking sequence (Figure 4.3).  Therefore, the elements 
conferring breed-specific expression of the porcine GnRHR gene reside within 1900 bp 
of proximal promoter. 
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Figure 4.2.  An SF-1 binding site is crucial for transcriptional activity of the porcine 
GnRHR gene in all three lines of swine.  Vectors containing a block replacement 
mutation of the SF-1 binding site in the context of the full-length promoter were 
constructed for all three lines of swine. These vectors, along with vectors containing 
full-length native GnRHR promoter for Control, Index, and Meishan lines of swine 
were transiently transfected into αT3-1 cells as described in Materials and Methods.  
Cells were harvested 24 h after transfection and assayed for luciferase (LUC) and β-
galactosidase activity.  Luciferase values were divided by β-galactosidase values to 
correct for transfection efficiency.  Transfections were performed a minimum of three 
times using three different vector preparations.  Values represent the mean ± SEM.  An 
asterisk indicates means that are greater than promoterless control (pGL3; P <0.05). 
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Figure 4.3.  Reduction of the full-length GnRHR gene promoters to 1900 bp for all 
three swine lines maintains breed divergence of promoter activity.  Luciferase (LUC) 
reporter vectors containing either 5000 or 1900 bp of proximal GnRHR promoter for 
all three lines of swine were transiently transfected into αT3-1 cells as described in 
Materials and Methods.  Cells were harvested 24 h after transfection and assayed for 
luciferase and β-galactosidase activity.  A reporter vector containing 600 bp of the 
murine GnRHR promoter was also transiently transfected as a positive control, as it 
has been shown to have robust activity in αT3-1 cells.  Luciferase activity was 
divided by β-galactosidase activity to adjust for transfection efficiency.  Values 
represent the mean ± SEM of at least three different transfections with three different 
vector preparations.  Unique letters within vector groups containing the same 
promoter length for each swine line indicate means that are different from one 
another (P <0.05). 
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The 500 bp region between -1900 and -1400 bp of the proximal porcine 
GnRHR gene promoter is not responsible for breed divergence in promoter activity.   
Upon sequence comparison of the -1900 promoters for the three lines, we identified a 22 
bp deletion (-1682 to -1661 bp) accompanied by a single bp substitution (-1684 bp) in the 
Meishan promoter compared to either the Index or Control promoters (Figure 4.4).  
Based on the sequence divergence between the Meishan and Index/Control promoters 
within the –1900 to –1400 bp region of proximal GnRHR promoter, we performed a 
promoter “swap” experiment, in which the 500 bp region between -1900 and -1400 bp of 
the Control and Meishan promoters were swapped within the context of the native full-
length promoter.  Although luciferase activity of the Meishan promoter decreased          
(P < 0.05) when manipulated to contain 500 bp of the Control promoter, activity of the 
Meishan GnRHR gene promoter maintained much higher levels than the full-length 
Control promoter (Figure 4.5.).  Alternatively, activity of the Control promoter 
containing 500 bp of Meishan promoter sequence remained at significantly lower levels 
than the full-length Meishan promoter (Figure 4.5).  Therefore, the region between -1900 
and -1400 bp of proximal GnRHR gene promoter does not appear to contain the 
element(s) responsible for divergence in GnRHR gene promoter activity between 
Meishan and Index/Control lines of swine. 
 
Divergent promoter activity of the GnRHR gene between lines of swine is lost 
with reduction of the 5’ flanking region to 1000 bp.  Transient transfection of αT3-1 
cells with plasmids containing sequential 5’ deletions of the -1900 GnRHR gene 
promoter for all three lines of swine revealed a loss of divergent luciferase activity for the 
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    -1688        -1655 
Control  ATATTTCCACTGAGAGCAATGGTTCAGTAGGCAC 
Index   ATATTTCCACTGAGAGCAATGGTTCAGTAGGCAC 
Meishan  ATATCT------------------------------------------------AGGCAC 
 
Figure 4.4.  The region between -1900 and -1400 bp of the Meishan GnRHR gene 
promoter contains a 22 bp deletion and single bp substitution compared to the Index and 
Control promoters.     
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Figure 4.5.  The 500 bp region between -1900 and -1400 bp of the GnRHR gene 
promoter is not responsible for the divergence in luciferase activity between the Control 
and Meishan lines.  Transient transfection of αT3-1 cells with GnRHR gene promoter 
“swap” constructs for Meishan and Control lines of swine was performed as described in 
Materials and Methods.  Luciferase (LUC) reporter vectors were constructed to contain 
the full-length Meishan or Control promoters with the 500 bp region between -1900 and  
-1400 bp “swapped” between lines.  Luciferase activity was divided by β-galactosidase 
activity to adjust for transfection efficiency.  Values represent the mean ± SEM of a 
minimum of three transfections with three different vector preparations.  Unique letters 
indicate means different from one another (P < 0.05). 
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Meishan line of swine (P < 0.05) when promoters were reduced from 1400 to 1000 bp of 
5’ flanking sequence (Figure 4.6).  Although still significantly greater than the Control 
promoter, there is a large decrease in activity of the Meishan promoter following 
reduction from -1400 bp to the proximal 1000 bp, suggesting the presence of an 
element(s) at least partially responsible for breed specificity within the -1400 to -1000 bp 
region of the GnRHR gene.   
 
A single bp substitution allows for divergent binding in the Meishan GnRHR 
gene promoter.  Sequence analysis of the -1400 to -1000 bp region of proximal promoter 
revealed five bp substitutions among the lines (Figure 4.7). Electrophoretic mobility shift 
assays (EMSAs) using radiolabeled oligonucleotides spanning each of these five single 
bp substitutions revealed that the alteration of a single bp at -1235, relative to the 
translational start site, allowed binding of nuclear proteins from αT3-1 cells to the 
oligonucleotide from the Meishan promoter, whereas the oligonucleotide representing the  
Control/Index promoter failed to bind protein (Figure 4.8).  Competition with 
oligonucleotides composed of the consensus binding sequences for AP-2, NF-κB, and 
Sp1 resulted in ablation of binding by the NF-κB and Sp1 consensus oligonucleotides 
(Figure 4.8).  Inclusion of an antibody directed against the p65 subunit of NF-κB in 
EMSAs with the oligonucleotide containing the bp substitution at -1235 of the Meishan 
GnRHR gene promoter revealed a supershift of the DNA-protein complex (Figure 4.9).  
Thus, the p65 subunit of NF-κB is a member of the protein complex binding to the region 
located between -1245 and -1225 bp of the Meishan promoter. 
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Figure 4.6.  Reduction of the porcine GnRHR gene promoter from 1400 to 1000 bp of 5’ 
flanking sequence causes a loss of divergence in luciferase activity among Control, Index 
and Meishan promoters.  Luciferase (LUC) reporter vectors containing 1900, 1400, 1000 
or 500 bp of proximal promoter for the GnRHR gene from all three lines of swine were 
constructed and transiently transfected into αT3-1 cells as described in Materials and 
Methods.  Cells were harvested and assayed for luciferase and β-galactosidase activity 24 
h after transfection.  Luciferase values were divided by β-galactosidase values in order to 
correct for transfection efficiency.  Values represent the mean ± SEM of at least three 
transfections with three different vector preparations.  Unique letters within vector groups 
containing the same promoter length for each swine line indicate means that are different 
from one another (P <0.05).   
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Figure 4.7.  Comparison of the Meishan, Index and Control GnRHR gene promoter 
sequences revealed five single bp substitutions among the lines within -1400 and -1000 
bp of proximal promoter.  Electrophoretic mobility shift assays using oligonucleotides 
representing each single bp substitution site within 1400 to 1000 bp of porcine GnRHR 
gene promoter indicated protein binding at -1235 bp in the Meishan promoter only. 
 
 
 
 
 
 
 
 
 
 
 
GSE GnRHR
-179
SF-1
-1900 -171-1400 -1000
-1000-1400
12345
Base Pair Substitutions Between Lines
-1235 -1211 -1110 -1094 -1027
 83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8.  A single bp substitution at -1235 bp relative to the translational start site of 
the porcine GnRHR gene allows for binding of αT3-1 nuclear protein to the Meishan but 
not the Control/Index promoter.  Electrophoretic mobility shift assays were performed by 
incubating radiolabeled oligonucleotides representing the -1245/-1225 bp region of 5’ 
flanking sequence for all three lines with nuclear extracts from αT3-1 cells.  The DNA-
protein complex was tested for specificity through competition with 50-fold molar excess 
of unlabeled homologous and heterologous DNA.  Additionally, the DNA-protein 
complex was challenged by competition with 50-fold molar excess of unlabeled 
oligonucleotides containing consensus binding sequences for AP-2, NF-κB and Sp1.  
Binding reactions and electrophoresis were performed as described in Materials and 
Methods. 
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Figure 4.9. The p65 subunit of NF-κB is a member of the specific complex binding to 
the oligonucleotide flanking the bp substitution at -1235 of the Meishan GnRHR gene 
promoter.  Electrophoretic mobility shift assay utilizing an oligonucleotide representing 
the -1225/-1245 bp region of the Meishan GnRHR gene promoter was incubated with 
nuclear extracts from αT3-1 cells.  Specificity of DNA:protein binding was tested by 
competition with 50-fold molar excess of unlabeled homologous and heterologous 
competitors.  Nuclear extracts were also incubated with an antibody directed against the 
p65 subunit of NF-κB (1 μg) or an equal mass of rabbit IgG.  Binding reactions and 
subsequent electrophoresis were performed as described in Materials and Methods. 
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Block replacement mutations of the NF-κB and Sp1 binding sites located  
between -1245 and -1225 bp of 5’ flanking region results in reduced activity of the 
Meishan GnRHR gene promoter.  Luciferase reporter vectors containing block 
replacement mutations of the binding elements for NF-κB (MμNF-κB), Sp1(MμSp1), or 
both (Mμ1240) within the context of the full-length promoter from the Meishan line were 
transiently transfected in αT3-1 cells to determine the importance of these binding 
elements in overall activity of the Meishan GnRHR gene promoter.  All three vectors 
containing block replacement mutations reduced luciferase activity (P < 0.05) 
approximately 25% when compared to the vector containing the native full-length 
Meishan promoter (Figure 4.10).  Luciferase activity for the vectors containing block 
replacement mutations was still significantly greater than the vector containing the full-
length Control promoter.  This suggests that while this region confers increased promoter 
activity of the Meishan GnRHR gene promoter, it acts synergistically with another 
unidentified element(s) within the Meishan proximal promoter. 
 
Discussion  
We have demonstrated a dramatic variance in GnRHR gene promoter activity 
among the Control, Index and Meishan lines of swine using transient transfections of 
αT3-1 cells with vectors containing the swine promoters.  The divergence in luciferase 
activity of reporter vectors containing the GnRHR gene promoter from Control, Index, 
and Meishan lines of swine illustrates a potential alteration in the mechanisms underlying 
transcriptional regulation of the GnRHR gene among lines of swine.  Ultimately, this 
may play a role in influencing the divergent ovulation rates and other reproductive traits  
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Figure 4.10.  Block replacement mutations of the NF-κB, Sp1 or both binding sites 
causes a reduction in luciferase activity of reporter constructs containing the full-length 
Meishan GnRHR promoter.  Transient transfection of αT3-1 cells with vectors containing 
block replacement mutations of the NF-κB or Sp1 binding sequences, as well as a double 
block replacement mutation were harvested 24 h after transfections and assayed for 
luciferase (LUC) and β-galactosidase activity.  Luciferase activity was divided by β-
galactosidase to adjust for transfection efficiency.  Values represent the mean ± SEM of 
three transfections with different vector preparations.  Unique letters indicate means that 
are different from one another (P < 0.05). 
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observed among the Control, Index and Meishan lines of swine.   
The maintenance of this difference remains as the promoter constructs are 
reduced from 5000 bp to 1400 bp of proximal promoter sequence, inferring that the 
element(s) responsible for the increased luciferase activity of the Meishan and Index 
promoter constructs is located within the proximal 1400 bp of the GnRHR gene 
promoter.  Such data is in keeping with evidence identifying the majority of elements 
responsible for basal and hormonally-induced expression of the GnRHR gene in other 
species are located within the proximal 1000 bp of flanking sequence (Clay et al., 1995; 
Duval et al., 1997; Ngan et al., 1999; White et al., 1999; Cheng et al., 2000; Cheng et al., 
2002; Kakar et al., 2002).  However, a “distal” regulatory element has been reported in 
the rat GnRHR gene promoter at -1200 bp upstream from the translational start site 
(Pincas et al., 1998).  
Transcriptional regulation of the GnRHR gene in different species is achieved 
through a variety of mechanisms and a number of transcription factors.  One of the most 
characterized mechanisms for transcriptional regulation of the GnRHR gene involves the 
orphan nuclear receptor, SF-1, known to be vital for cell-specific expression of the 
GnRHR gene in the human (Ngan et al., 1999), mouse (Duval et al., 1997b), rat (Pincas 
et al., 2001), sheep (Duval et al., 2000) and pig (Cederberg et al., unpublished data). 
Steroidogenic factor-1 binding is also known to confer gonadotrope-specific expression 
of the gonadotropin subunit genes (Barnhart and Mellon, 1994; Keri and Nilson, 1996; 
Brown and McNeilly, 1997).  Although an SF-1 binding site is a member of the cell-
specific promoter for the porcine GnRHR gene promoter (Cederberg et al., unpublished 
data), we have shown that SF-1 does not contribute to breed-specific regulation of the 
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GnRHR gene in swine.   
Additionally, AP-1 has been implicated in basal expression of the human GnRHR 
gene (Cheng et al., 2000) and basal and GnRH-stimulated activity the mouse GnRHR 
gene promoter (Duval et al., 1997; White et al., 1999).  A variety of GATA family 
members and LIM-related factors (Pincas et al., 2001) are known to play a role in 
regulation of the GnRHR gene in both gonadotropes and human placenta.  In addition, 
Oct-1 is thought to influence the human GnRHR gene promoter, serving as an activator 
(Cheng et al., 2001) or repressor (Cheng et al., 2002) at specific sequences of the human 
GnRHR gene promoter.     
 Our identification of an NF-κB site included in breed-specific expression of the 
porcine GnRHR gene in gonadotrope cells was unique.  Although NF-κB is traditionally 
associated with genes involved in immune and inflammatory responses (Hayden and 
Ghosh, 2004), it has been implicated in mediating the apoptotic effects of GnRH in 
ovarian cancer cells (Gründker et al., 2000).  Gründker and coworkers (2000) illustrated a 
mechanism of GnRH in suppression of chemotherapy-induced apoptosis that may be 
mediated through activation of NF-κB.  Regarding the role of GnRHR in the gonadotrope 
cell of the anterior pituitary gland, however, NF-κB remains noticeably absent from the 
cast of transcription factors known to play a role in regulation of the GnRHR or 
gonadotropin subunit genes.  In point of fact, the NF-κB signaling system has not 
previously been identified in gonadotropes.  However, NF-κB binding sites have been 
associated with regulation of genes expressed in other pituitary cell types including 
somatotropes (Karalis et al., 2004) and corticotropes (Parnet et al., 2003).  Additionally, 
NF-κB is increased in response to activators of the protein kinase A (PKA) signaling 
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pathway in Sertoli cells, and may regulate gene expression during spermatogenesis within 
the testis in a stage-specific manner (Delfino and Walker, 1998).  Taken together, these 
data illustrate the unique mechanisms utilized by the Meishan line of swine in 
employment of a signaling pathway distinct from the Control and Index lines of swine.  
 This region of the Meishan GnRHR gene promoter appears to also bind another 
transcription factor capable of recognizing the Sp1 consensus binding site.  Although the 
use of an Sp1 consensus oligonucleotide revealed competition for DNA:protein binding, 
the lack of antibody binding to the DNA:protein complex (data not shown) suggests that 
a transcription factor that recognizes the same consensus binding sequence may be 
competing rather than Sp1.  One such candidate transcription factor is Sp3.  Closely 
related to Sp1, Sp3 and Sp1 belong to the same transcription factor family and exhibit 
highly homologous zinc-finger DNA binding domains (Philipsen and Suske, 1999).  Due 
to the sequence homology between the two proteins, Sp1 and Sp3 also frequently 
recognize the same binding sequences (Al-Sarraj et al., 2005).  Although Sp3 was 
originally found to repress Sp1 transcriptional activation by competing for binding sites 
(Hagen et al., 1994), Sp3 has also been shown to act as an activator of transcription in 
some instances (Udvadia et al., 1995).  Interestingly, the action of Sp3 in regulating 
transcription is determined by the number of recognition sites for Sp3 on the promoter; 
those promoters containing one Sp3 element are activated, whereas those harboring 
multiple binding sites display a weak response, at best, to Sp3 (Dennig et al., 1996).  In 
addition, there are three isoforms of Sp3, a full-length and two truncated species  
(Philispen and Suske, 1999); the relative abundance of the three isoforms within a cell 
may influence transcriptional regulation by Sp3.   
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Sp3 has also been shown to bind to consensus NF-κB binding sites (Liu et al., 
2004).  Perhaps more interesting is the finding by Liu and coworkers (2004) that the 
flanking sequence of the consensus NF-κB binding site may in part moderate the 
transcription factors recruited to the binding element.  Data in Drosophila also suggests 
that in some instances Sp3 can compensate for Sp1 binding when Sp1 is not present, in 
formation of an Sp1/Sp3:NF-κB complex (Ping et al., 2000).  Such data may help explain 
the apparent importance of the DNA sequence surrounding the bp mutation at -1235 in 
the Meishan GnRHR gene promoter.  Use of an antibody in supershift assays remains to 
be performed in order to determine if Sp3 is indeed binding to the Meishan GnRHR gene 
promoter at -1235 bp relative to the translational start site. 
 Mutation of the binding sites for NF-κB (MμNF-κB) and Sp1 (MμSp1) within the 
Meishan GnRHR gene promoter demonstrates a significant loss of promoter activity.  In 
addition, mutation of both the NF-κB and the Sp1 recognition sequences (Mμ1240) 
dropped luciferase activity to approximately the same level as either single block 
mutation.  Due to the lack of further ablation of luciferase activity by the double block 
replacement mutation, it would appear that the transcription factors binding to the two 
elements work synergistically, but not additively, to stimulate increased GnRHR gene 
promoter activity in the Meishan line of swine.  In addition, none of the mutations 
lowered Meishan GnRHR promoter activity to that of the native full-length Control 
promoter, indicating that, although the complex of transcription factors at -1242/-1230 of 
the Meishan GnRHR gene promoter serves to increase GnRHR gene transcription, there 
is another element(s) within the Meishan GnRHR gene promoter that also confers breed- 
specific expression. 
 91 
 In conclusion, the large variance in GnRHR gene promoter activity among the 
Control, Index, and Meishan lines of swine appears to be due, in part, to binding of the 
p65 subunit of NF-κB and an unknown transcription factor that recognizes an Sp1 
consensus binding sequence (Figure 4.11).  Although mutation of this region does reduce 
Meishan GnRHR promoter activity (P < 0.05), it remains significantly higher than the 
activity of the promoter from the Control line.  Thus, it can be deduced that the promoter 
region to which a complex containing the p65 subunit of NF-κB and its unidentified 
partner binds in the Meishan line is important, but not solely responsible for the increased 
activity observed in the Meishan compared to Control and Index GnRHR gene 
promoters.  To our knowledge, we have demonstrated a unique role for NF-κB in gene 
regulation within the gonadotrope cell of the anterior pituitary gland. 
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Figure 4.11.  Working model of the breed-specific promoter for the GnRHR gene in 
Meishan and white-crossbred (Control/Index) lines of swine.  A single bp substitution in 
the Meishan GnRHR gene promoter allows for binding of a complex of transcription 
factors including the p65 subunit of NF-κB and an unknown protein capable of binding to 
a consensus Sp1 binding site. 
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